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Reporting of stepped wedge cluster randomised trials:  extension 
of the CONSORT 2010 statement with explanation and 
 elaboration
Karla Hemming,1 Monica Taljaard,2,3 Joanne E McKenzie,4 Richard Hooper,5 Andrew Copas,6  
Jennifer A Thompson,6,7 Mary Dixon-Woods,8 Adrian Aldcroft,9 Adelaide Doussau,10  
Michael Grayling,11 Caroline Kristunas,12 Cory E Goldstein,13 Marion K Campbell,14  
Alan Girling,1 Sandra Eldridge,5 Mike J Campbell,15 Richard J Lilford,16 Charles Weijer,13 
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This report presents the Consolidated 
Standards of Reporting Trials 
(CONSORT) extension for the stepped 
wedge cluster randomised trial (SW-
CRT). The SW-CRT involves 
randomisation of clusters to different 
sequences that dictate the order (or 
timing) at which each cluster will switch 
to the intervention condition. The 
statement was developed to allow for 
the unique characteristics of this 
increasingly used study design. The 
guideline was developed using a 
Delphi survey and consensus meeting; 
and is informed by the CONSORT 
statements for individual and cluster 
randomised trials. Reporting items 
along with explanations and examples 
are provided. We include a glossary of 
terms, and explore the key properties 
of the SW-CRT which require special 
consideration in their reporting.
The CONSORT (Consolidated Standards of Reporting 
Trials) statement, initially published in 1996 and 
updated in 2001 and 2010, outlines essential items to 
be reported in a parallel arm individually randomised 
trial.1  2  3 The CONSORT extension for cluster 
randomised trials (CRTs), initially published in 2004 
and updated in 2012, extended this guidance for trials 
in which groups of individuals (clusters, see table 1 for 
a full glossary of terms) are randomised to different 
treatment conditions.4  5 In recent years, a novel type 
of cluster randomised design—stepped wedge cluster 
randomised trial (SW-CRT)—has become increasingly 
popular.6  7  8 The SW-CRT involves randomisation 
of clusters to different sequences. These sequences 
dictate the order (or timing) with which each cluster 
will switch to the intervention condition.
The basic components of the design, as well as 
illustrative examples of studies which have used this 
design, have been described previously.9 The unit 
of randomisation in these trials is the cluster with 
clusters (or groups of clusters) allocated to different 
sequences (as opposed to different arms in a parallel 
trial). These sequences specify the number of periods 
spent in the control condition and the number of 
periods in the intervention condition. Figure 1 shows 
an example of four groups of clusters allocated to 
four different sequences. Each cluster contributes 
data to the analysis from each measurement period. 
In the example in figure 1 there are five measurement 
periods. The point at which a cluster switches to the 
intervention condition is called a step. Sometimes a 
transition period is built into the design, during which 
the intervention is implemented in the cluster.
This design has numerous methodological 
complexities, including potential confounding 
with time;10 changes in correlation structures 
over time;11  12  13 the possibility of within cluster 
contamination;14 the possibility of time varying 
treatment effects;10  15 and different design 
variations,16 17 all of which increase the complexity of 
reporting.9 Perhaps unsurprisingly, systematic reviews 
examining the adequacy of reporting of SW-CRTs 
have revealed numerous inadequacies, including the 
absence of essential details of the design; inconsistent 
use of terminology;6 7 8 18 19 frequent lack of clarity in 
reporting of adjustment for time effects;20 and frequent 
failure to report ethical review and trial registration.19 
These findings suggest there is a need for a specific 
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SUMMARY POINTS
•  The stepped-wedge cluster randomised trial (SW-CRT) is a novel cluster 
randomised trial variant that is increasingly being used. It is particularly 
relevant for evaluating service innovations in learning healthcare 
organisations
•  There has been an exponential increase in the use of this design over the 
past few years with an expected increase in publications in the near future. 
A number of systematic reviews have demonstrated poor reporting of key 
features of SW-CRTs
•  We report a CONSORT extension for the SW-CRT design. The reporting guideline 
highlights the additional complexities of the design
•  We are in the unique position of potentially being ahead of the curve with 
great potential to improve reporting of this innovative design by defining 
reporting criteria before its widespread use. We strongly recommend use of 
this reporting guideline in any future SW-CRT report
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reporting guideline for this trial design. Here we 
report the results of a consensus process to develop 
an extension to the CONSORT statement for use with 
SW-CRTs. The goal of this extension is to improve 
the standards of reporting of this important and 
increasingly used research design.
Scope of this statement
This reporting statement should be followed when 
reporting results from any SW-CRT. In line with other 
CONSORT statements, this guideline includes the 
minimum set of items that should be reported. It is 
not intended to be a comprehensive list of all possible 
items that could be reported.
A wide variety of terms have been used to describe 
aspects of the SW-CRT design. Figure 1 shows the key 
components of the design and table 1 shows a glossary 
of terms for this reporting statement. Generally, SW-
CRTs have a minimum of three sequences. Trials with 
two sequences and three periods, for example, a two 
arm CRT in which both arms are initially observed under 
the control condition and in addition, the control arm 
adopts the intervention during a third measurement 
period might also technically be considered a SW-CRT. 
The statement was developed for comparisons of two 
treatment conditions. To take a broader perspective on 
the range of designs that can be included, we are not 
restricting our definition to designs with all clusters 
initiating in the control condition and ending up in the 
intervention condition.21
Extending the CONSORT statement to SW-CRTs
We developed this extension using methods 
recommended for developing reporting guidelines.22 
We registered our protocol on the Enhancing the 
QUAlity and Transparency Of health Research 
(EQUATOR) website in July 2015 and identified relevant 
and related reporting guidelines.23 We conducted 
several systematic reviews of published SW-CRTs 
examining aspects of reporting and methodological 
conduct and undertook a consensus process.
Results from systematic reviews examining SW-CRT 
methods and reporting
We conducted several systematic reviews in advance of 
the consensus process.8 18 19 20 Martin et al found that 
Table 1 | Glossary of terms
Term Explanation
Closed cohort A study design in which participants are repeatedly assessed over a series of measurement points and cannot join the study once it has started.
Cluster The unit of randomisation.
Cluster-period A grouping of observations by time of measurement and cluster.
Complex intervention An intervention that has multiple and interacting parts.
Control condition The comparator treatment.
Cross-sectional A study design in which different participants are measured at each measurement occasion.
Duration of period Time (eg, months) between each step.
Intervention condition* The treatment under evaluation.
Open cohort A study design in which participants are repeatedly assessed over a series of measurement points and can join and leave the study throughout its duration.
Participant A participant is someone on whom investigators seek to measure the outcome of interest.
Period A grouping of observations by time of measurement.
Purposively collected data Data that are collected for the specific purpose of contributing to the trial (data that are not routinely collected).
Research participant A research participant denotes a human research subject from the standpoint of ethical considerations.
Sequence of treatments (often abbreviated 
to sequence or allocated sequence)*
A sequence of codes defining the order of implementation of the treatment conditions for 
each cluster. More than one cluster can be allocated to each sequence.
Step A planned point at which a cluster or group of clusters crosses from control to intervention.
Transition period The time needed to fully embed the intervention. A transition period may have the same or different duration than a measurement period.
*Note the CONSORT statement uses the term group to refer to the allocated treatment, but for stepped wedge cluster randomised trials we distinguish 
between the concepts of the allocated sequence and the treatment condition in any given period of that sequence, and avoid terminology such as group 
or arm. We use the term treatment in a generic way to refer to either the active treatment or comparator; and retain the use of the phrase intervention 
condition to refer to the active treatment of the trial; and the control condition to refer to the comparator.
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Fig 1 | Diagram of the standard stepped wedge cluster 
randomised trial. Note that in designs where participants 
are measured after a follow-up time from their exposure, 
then the periods and their representations are defined 
based on when an individual was exposed and not when 
measured
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the SW-CRT is increasingly being used.8 Most trials 
are conducted in advanced economies and healthcare 
settings. A noticeable minority of trials are conducted 
in lower middle income settings. Most trials have fewer 
than 20 clusters and a smaller number of time periods.8
Reviews of the quality of reporting of sample 
size and analysis methods revealed incomplete or 
inadequate reporting overall, and specifically, a lack of 
reporting of how time effects and extended correlation 
structures were incorporated both at the design and 
analysis stages.8 15 18 20 Reviews of the ethical conduct 
and reporting revealed that many SW-CRTs do not 
report research ethics review; do not clearly identify 
from whom and for what consent was obtained; and 
a considerable number do not preregister with a 
trial registration database.19 Reviews of the method 
literature have identified several key aspects of the SW-
CRT which are associated with bias.20 24 Clear reporting 
of these aspects is essential to make interpretation of 
trial results in published reports possible.
Firstly, time is a potential confounder in a SW-
CRT and requires special consideration both at the 
design and analysis stage.10  25 Secondly, as the SW-
CRT is a longitudinal and clustered study, correlation 
structures are more complex than those of a parallel 
CRT carried out at a single cross section in time.12 
Thirdly, some SW-CRTs are at risk of within cluster 
contamination. Within cluster contamination can arise 
either when outcomes in the intervention condition 
are obtained from participants who are yet to be 
exposed to the intervention, or alternatively, when 
outcome assessments in the control condition are from 
participants already exposed to the intervention.14 
Contamination arising from observations yet to be fully 
exposed to the intervention condition can be allowed 
for by building transition periods into the design; or 
by modelling these effects (referred to as lag effects).9 
Interactions between time and treatment can also 
arise. These time varying effects are more likely to arise 
when the intervention is not continuously delivered, 
does not create a permanent change, or where its 
impact might decrease or increase over time.15
These complexities differ according to the many ways 
that a SW-CRT can be conducted, including whether the 
same or different participants are repeatedly assessed, 
whether participants are continuously recruited and 
the duration of their exposure, and whether a complete 
enumeration of the cluster is taken.9  14 Practical and 
ethical issues must be considered when adopting 
this design.17  26Table 2 provides a summary of key 
methodological issues which need extra consideration 
when reporting a SW-CRT.
Consensus process
Members of the working group (KH, MT, JEM, ABF, CW, 
and JMG) identified items from the original CONSORT 
statement which required modification; considered 
whether the modification used in the cluster extension 
was appropriate; and if not, proposed a modified 
version for the item. In a modified Delphi process 
(December 2016), we invited 64 subject matter experts 
to consider, rate, and comment on the proposed 
modifications of whom 42 completed the survey. We 
summarised responses from the survey and circulated 
a second draft of the proposed modifications in 
advance of a one day consensus meeting (Liverpool 
May 2017). The CONSORT stepped wedge consensus 
group (20 people in total all listed as authors of this 
statement) consisted of members of the working group 
and those with expertise in trial design, journal editors 
(BMJ Open, Trials, Clinical Trials, and BMJ Quality, 
and Safety Improvement), ethicists, statisticians, 
methodologists, and developers of reporting guidelines 
(cluster trials, pilot and feasibility trials, and equity 
trials). At the meeting, proposed wording, examples, 
and elaboration of text were discussed and amended. 
The final draft was then circulated and comments were 
incorporated.
The CONSORT extension for SW-CRT
Table 3 shows a checklist of the 26 items to be 
reported in the publication of a SW-CRT. Some items 
have not been modified from the original CONSORT 
statement, some are modified, and some are new. 
Similar to the CONSORT extension for cluster trials, 
item 10 (implementation of randomisation) has been 
replaced by items 10a, 10b, and 10c. In recognition 
of the under-reporting of key ethical aspects of these 
trials, a new item on research ethics review has been 
added as item 26 (as was added to the CONSORT 
extension for pilot and feasibility studies).27 For ease 
of interpretation in the elaboration that follows, we 
provide the original CONSORT wording, the wording 
of the CONSORT extension for CRTs, as well as the 
wording for the SW-CRT extension. Box 1 summarises 
key changes to the original CONSORT statement and 
substantial deviations from the CONSORT extension 
for CRTs. We have provided examples and explanations 
for most items. Where the item has not been modified 
or the modification is only minor, readers are referred 
to the original statements for full explanation and 
elaboration.3  5 For some items, which have not been 
modified, an example or explanation has been 
provided where this item raises specific nuances under 
the SW-CRT. Given differences in terminology used to 
describe the SW-CRT and the significant number of 
modified items, the items in this statement have been 
written to replace the original CONSORT items; and 
therefore, should not be considered extensions to the 
original items.
Title and abstract
Item 1a Title
Standard CONSORT item—Identification as a 
randomised trial in the title.
CONSORT cluster extension—Identification as a CRT 
in the title.
Extension for SW-CRTs—Identification as a SW-CRT 
in the title.
Example—“The Devon Active Villages Evaluation 
(DAVE) trial of a community-level physical activity 
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intervention in rural south-west England: a stepped 
wedge cluster randomised controlled trial.”28
Explanation—One reason for including the type 
of study design in the title is to facilitate accurate 
identification of relevant studies in systematic reviews. 
Other reasons including alerting readers to key 
important features of the study design. A wide variety 
of different terminology is currently used to describe 
the SW-CRT. These include the “multiple-period 
baseline design” and the “wait list design” (although 
not every multiple-period baseline design and wait list 
design will be a SW-CRT). Adoption of a single term 
will improve the identification of these studies and 
differentiate studies which are not SW-CRTs. Reporting 
of parallel CRTs improved with the adoption of the 
single term “cluster” rather than the mix of terms (such 
as “group randomised” or “field trial”).29 It can also be 
useful to report any trial acronym in the title, to aid 
future searches for the study.
Item 1b: Abstract
Standard CONSORT item—Structured summary of trial 
design, methods, results, and conclusions (for specific 
guidance see CONSORT for abstracts).
CONSORT cluster extension—Abstract see table (not 
shown).
Extension for SW-CRTs—Structured summary of 
trial design, methods, results, and conclusions (see 
table 4).
For the same rationale as provided in the other 
CONSORT statements, clear reporting of the trial’s 
objectives, design, methods, main results, and 
conclusions in the abstract is crucial. The primary 
reason for this is that many readers will base their 
assessment of the trial from the information available 
in the abstract.30 A review assessing the quality of 
reporting of abstracts from fully published SW-CRT 
revealed incomplete reporting of important details.31 
A set of items to be reported as a minimum in an 
Table 2 | Key method considerations to consider in the reporting of a SW-CRT
Concept Description Why this is important Mitigating strategies
Imbalance of the 
design with respect 
to time
In a SW-CRT, clusters are randomised to different 
sequences which dictate the order they initiate 
the intervention. Observations collected under the 
control condition are, on average, from an earlier 
calendar time than observations collected under the 
intervention condition.
Changes external to the trial may create underlying 
secular trends. In addition, where the same partic-
ipants are repeatedly assessed, their health status 
might improve (or worsen) over the study. Time is a 
potential confounder because it is associated with 
both the treatment condition and the outcome.
Analysis and sample size should allow for the 
confounding effect of time.
Repeated measures 
on same clusters 
and possibly same 
participants
SW-CRTs make a series of measurements over 
time within each cluster. These repeated measure-
ments can be on the same participants, different 
participants, or a mixture of the same and different 
participants at each measurement.
Correlation structures are more complex than in 
a parallel cluster trial conducted at a single cross 
section in time.
Analysis (and consequently sample size 
calculations) should allow for the fact that 
data are not independent and dependencies 
might vary over time.
Within cluster 
contamination
In SW-CRTs, some or all of the clusters will be 
exposed to both the control and intervention 
conditions. Participants can either have a relatively 
short exposure to the intervention (eg, surgical 
intervention) or long exposure (eg, change in care 
home policy).
Where the duration of exposure is short it is unlikely 
that individuals will be exposed to both the control 
and intervention condition. Where the duration of 
exposure is long, it may be possible that some par-
ticipants are exposed to both the control condition 
and the intervention condition.
In trials with long exposure, delayed 
assessment of outcomes should be avoided 
to prevent participants recruited under the 
control condition later becoming exposed to 
the intervention condition.
Delayed  treatment 
effects and 
 transition periods
The effect of the intervention may be immediate, or 
there may be a delay before its effect is realised.
When there is a delay before the effect of the inter-
vention is realised the estimate of effectiveness can 
be attenuated.
Where there is an expected delay before the 
effect of the intervention is materialised a 
transition period can be built into the design 
of the study.
Time by treatment 
effect interactions
SW-CRTs can evaluate interventions of many differ-
ent forms. The intervention can be a one-off delivery 
involving a permanent change to a healthcare sys-
tem, or it can be an intervention which may need to 
be repeated multiple times to ensure its effects are 
realised such as education of health professionals. 
Sometimes the intervention may be refined over the 
duration of the study.
Interventions delivered at a single occasion (and not 
repeated to ensure it creates a permanent effect) 
might have an impact which changes with increasing 
time since exposure (eg, the effect of the interven-
tion might be quite large immediately after exposure 
and then its impact might start to decrease). If 
interventions are refined over time then their effect 
will also change over the duration of the study.
If interventions are either refined over time 
or are not expected to create a permanent 
effect, an analysis examining how the effect 
of the treatment changes with time should be 
considered.
Sampling of 
 observations
SW-CRTs can take a complete enumeration of the 
cluster, a random sample of individuals, or recruit 
participants into the trial. Furthermore, participants 
might be continuously recruited into the trial as they 
present; or all participants might be recruited at the 
beginning of the trial.
Information on how observations were sampled is 
important to elicit risks of bias. Studies which take a 
complete enumeration have lower risks of bias as do 
studies which recruit all participants at a fixed point 
in time before randomisation has occurred. Studies 
which continuously recruit participants have higher 
potential for identification and recruitment biases.
Methods to reduce the risk of bias include 
taking a complete enumeration of the entire 
cluster-period, recruiting all participants 
before randomisation, and having someone 
independent to the study perform the 
recruitment.
Continuous or 
discrete time 
 measurements
Observations may be accrued continuously (eg, as 
patients present to an emergency department and 
provide measurements after a follow-up period), or 
discretely (eg, a survey questionnaire may be imple-
mented at several discrete points in time).
Where observations are accrued in continuous time, 
outcomes are more likely to be measured in contin-
uous time. Where outcomes are accrued in discrete 
time, outcomes are more likely to be measured in 
discrete time.
Collecting exact timings of outcomes will 
ensure the full possible range of analysis 
methods can be implemented.
Justification of study 
type
Justifying the need for a staggered exposure of the 
intervention using a SW-CRT, as opposed to a simple 
parallel arm implementation, is important because 
the SW-CRT is more complicated in its design, 
analysis, and implementation than the parallel CRT. 
It might also involve exposing a greater number of 
clusters or participants to the intervention.
Risks of bias in the SW-CRT may be higher than in a 
parallel CRT. For example, secular trends may be of 
concern in a SW-CRT, but not in a parallel design.
SW-CRTs should be classified as research and 
so should be registered as a trial and should 
be submitted for review to an approved 
research ethics committee.  o
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Table 3 | Checklist of information to include when reporting a stepped wedge cluster randomised trial (SW-CRT)
Topic Item no Checklist item Page no
Title and abstract
1a Identification as a SW-CRT in the title.
1b Structured summary of trial design, methods, results, and conclusions (see separate SW-CRT checklist for abstracts).
Introduction
Background and 
objectives
2a Scientific background. Rationale for using a cluster design and rationale for using a stepped wedge design.
2b Specific objectives or hypotheses.
Methods
Trial design 3a Description and diagram of trial design including definition of cluster, number of sequences, number of clusters randomised 
to each sequence, number of periods, duration of time between each step, and whether the participants assessed in different 
periods are the same people, different people, or a mixture.
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons.
Participants 4a Eligibility criteria for clusters and participants.
4b Settings and locations where the data were collected.
Interventions 5 The intervention and control conditions with sufficient details to allow replication, including whether the intervention was 
 maintained or repeated, and whether it was delivered at the cluster level, the individual participant level, or both.
Outcomes 6a Completely defined prespecified primary and secondary outcome measures, including how and when they were assessed.
6b Any changes to trial outcomes after the trial commenced, with reasons.
Sample size 7a How sample size was determined. Method of calculation and relevant parameters with sufficient detail so the calculation can 
be replicated. Assumptions made about correlations between outcomes of participants from the same cluster. (see separate 
checklist for SW-CRT sample size items).
7b When applicable, explanation of any interim analyses and stopping guidelines.
Randomisation
Sequence generation 8a Method used to generate the random allocation to the sequences of treatments.
8b Type of randomisation; details of any constrained randomisation or stratification, if used.
Allocation concealment 
mechanism
9 Specification that allocation was based on clusters; description of any methods used to conceal the allocation from the clusters 
until after recruitment.
Implementation 10a Who generated the randomisation schedule, who enrolled clusters, and who assigned clusters to sequences.
10b Mechanism by which individual participants were included in clusters for the purposes of the trial (such as complete enu-
meration, random sampling; continuous recruitment or ascertainment; or recruitment at a fixed point in time), including who 
recruited or identified participants.
10c Whether, from whom and when consent was sought and for what; whether this differed between treatment conditions.
Blinding 11a If done, who was blinded after assignment to sequences (eg, cluster level participants, individual level participants, those 
assessing outcomes) and how.
11b If relevant, description of the similarity of treatments.
Statistical methods 12a Statistical methods used to compare treatment conditions for primary and secondary outcomes including how time effects, 
clustering and repeated measures were taken into account.
12b Methods for additional analyses, such as subgroup analyses, sensitivity analyses, and adjusted analyses.
Results
Participant flow  
(a diagram is strongly 
recommended)
13a For each treatment condition or allocated sequence, the numbers of clusters and participants who were assessed for eligibility, 
were randomly assigned, received intended treatments, and were analysed for the primary outcome (see separate SW-CRT flow 
chart).
13b For each treatment condition or allocated sequence, losses and exclusions for both clusters and participants with reasons.
Recruitment 14a Dates defining the steps, initiation of intervention, and deviations from planned dates. Dates defining recruitment and 
 follow-up for participants.
14b Why the trial ended or was stopped.
Baseline data 15 Baseline characteristics for the individual and cluster levels as applicable for each treatment condition or allocated sequence.
Numbers analysed 16 The number of observations and clusters included in each analysis for each treatment condition and whether the analysis was 
according to the allocated schedule.
Outcomes and esti-
mation
17a For each primary and secondary outcome, results for each treatment condition, and the estimated effect size and its precision 
(such as 95% confidence interval); any correlations (or covariances) and time effects estimated in the analysis.
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended.
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing prespecified from 
exploratory. 
Harms 19 Important harms or unintended effects in each treatment condition (for specific guidance see CONSORT for harms).
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses.
Generalisability 21 Generalisability (external validity, applicability) of the trial findings. Generalisability to clusters or individual participants, or 
both (as relevant).
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence.
Other information
Registration 23 Registration number and name of trial registry.
Protocol 24 Where the full trial protocol can be accessed, if available.
Funding 25 Sources of funding and other support (such as supply of drugs), and the role of funders.
Research ethics review 26 Whether the study was approved by a research ethics committee, with identification of the review committee(s). Justification 
for any waiver or modification of informed consent requirements.
This table can be downloaded as a separate document in supplementary materials 3; page numbers can be added electronically to the PDF document.
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abstract of a SW-CRT is included in table 4. Of some 
note, the items recommended to be reported in the 
abstract results section do not include the summary 
measures of the outcome under intervention and 
control conditions, so as to avoid misattributing 
the unadjusted difference to the treatment effect. 
A worked example of an abstract according to this 
template is provided (see supplementary materials, 
table S1).32
Introduction
Item 2a: Background
Standard CONSORT—Scientific background and 
explanation of rationale.
CONSORT cluster extension—Rationale for using a 
cluster design.
Extension for SW-CRTs—Scientific background. 
Rationale for using a cluster design and rationale for 
using a stepped wedge design.
Example 1 (Scientific background)—“In 2008, the 
World HealthE Organization (WHO) introduced the 
Surgical Safety Checklist (SSC) designed to improve 
consistency of care. The pilot pre-/post evaluation 
of the WHO SSC across 8 countries worldwide, 
which found reduced morbidity and mortality after 
SSC implementation, constituted the first scientific 
evidence of the WHO SSC effects. A number of 
subsequent studies to date have reported improved 
patient outcomes with use of checklists. Furthermore, 
checklists have also been shown to improve 
communication, preparedness, teamwork, and safety 
attitudes—findings that have been corroborated by 
a recent systematic review. Although checklists are 
becoming a standard of care in surgery, the strength of 
the available evidence has been criticized as being low 
because of (i) predominantly pre /post implementation 
designs without controls; (ii) lack of evidence on effect 
on length of stay; and (iii) lack of evidence on any 
Box 1 | Noteworthy changes to the CONSORT 2010 statement and deviations from the 2012 extension for cluster trials
Noteworthy changes to the CONSORT 2010 statement
Separate presentation of the CONSORT checklist items for SW-CRTs (see table 3).
Modification of item 2a (Background) to include rationale for use of a stepped wedge design.
Extension of item 3a (Design) to include a schematic representation of the design; and clarity over key design aspects (such as number of    
steps, number of observations per cluster-period).
Extension of item 7a and 12a (Sample size and Statistical methods) to include reference to the methods used to allow for adjustment for 
time and assumptions made about correlations.
Extension of item 12b (Auxiliary analyses) to include any sensitivity analyses for assumptions made about time effects.
Extension of item 13a (Participant flow) to include a modified flow-chart by allocated sequence (see fig 3).
Extension of item 17a (Outcomes and estimation) to report any adjustment for time effects; and presentation of secular trends (see 
 supplementary materials, fig S2).
Extended elaboration under item 18 (Auxiliary analyses) to include reporting of any sensitivity analyses for any model based methods; and 
extended elaboration under item 20 (Limitations) to include discussion of any limitations due assumptions made about time effects.
Extended elaboration under item 5 (Interventions) to include planned details on timings of interventions; and under item 6 (Outcomes) 
timings of outcome assessments. This information, along with the corresponding realised dates under item 14a (Recruitment dates) 
allow determination of the risk of within cluster contamination.
Addition of item 26 (Research ethics review) to include reporting of ethical review and consent processes.
Noteworthy deviations from the CONSORT 2012 extension for cluster randomised trials
Modification of wording of item 2b (Objectives) from “Whether objectives pertain to the cluster level, the individual participant level or 
both.” which was deemed ambiguous to “Specific objectives or hypotheses.”
Modification of item 9 (Allocation concealment) to reference only allocation concealment from the unit of randomisation (ie, cluster) and 
not participant (comes under item 10b).
Table 4 | Items to report in the journal abstract of a stepped wedge cluster randomised trial (SW-CRT)
Abstract item Extension for SW-CRTs
Title Identification of study as a SW-CRT
Trial design Description of the trial design (including numbers of sequences and clusters, and whether participants 
 assessed in different periods are the same people, different people, or a mixture)
Methods:
 Participants Eligibility criteria for clusters and participants
 Interventions The intervention and control conditions
 Objective Specific objective or hypothesis
 Outcome Clearly defined primary outcome
 Randomisation How clusters were allocated to sequence of treatments
 Blinding (masking) Whether participants, healthcare professionals, those recruiting and those assessing outcomes were blinded
Results:
 Numbers randomised Number of clusters randomised to each sequence of treatments
 Recruitment Trial status
 Numbers analysed Number of observations and clusters included in the analysis
 Outcome For the primary outcome, the estimated effect size (confidence interval) and reporting of any adjustment for 
secular trends
 Harms Important adverse events or side effects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register 
Ethical approvals
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associated cost savings. Randomized controlled trials 
(RCTs) are required….”33
Example 2 (Rationale for cluster randomisation and 
stepped wedge design)—“A stepped wedge cluster 
randomised controlled design was chosen following 
piloting to facilitate roll out of the intervention, …, and 
prevent contamination and disappointment effects in 
hospitals not randomised to the intervention.”34
Explanation—The need for any randomised 
evaluation of an intervention, whether randomising 
clusters or individuals should be justified. This 
justification should refer to the best available evidence 
for similar interventions. Reasons why current evidence 
is lacking should be articulated (as in example 1).
As with any trial design, key aspects of the design 
should be justified. In the SW-CRT, this justification 
includes the use of cluster randomisation, the need 
to roll out the intervention to all clusters (where this 
is the case), and the need for staggered roll-out of the 
intervention.16 Justifying cluster randomisation is 
important because cluster randomisation increases 
the sample size and this, in turn, might expose more 
participants to interventions of unknown effectiveness. 
Justifying the need for a staggered roll-out of the 
intervention using a SW-CRT, as opposed to a simple 
parallel arm implementation, is important because the 
SW-CRT is more complicated in its design, analysis, and 
implementation than the parallel CRT. Risks of bias in 
the SW-CRT may be higher than in a parallel CRT. For 
example, secular trends may be of concern in a SW-
CRT, but not in a parallel design.10 Risks of bias arising 
from identification and recruitment of participants 
may also be higher because in a SW-CRT it may be more 
difficult to blind people recruiting participants to the 
cluster’s allocation status. The design is consequently 
viewed by some as potentially providing a lower level 
of evidence compared to the parallel CRT.7 35 36
Some possible justifications for adopting the 
stepped wedge design include that the intervention 
will be rolled out regardless of the research study,17 
availability of an inadequate number of clusters to 
achieve the target power in a parallel design,37 to 
increase statistical efficiency,11  38  39 or to facilitate 
recruitment when engagement of clusters is only 
forthcoming on some promise of the intervention (as 
in example 2).
Although staggering the roll-out may appeal to 
researchers with limited resources for delivering the 
intervention simultaneously, this is not in itself a 
legitimate argument for a SW-CRT.40 Providing the 
intervention to all clusters might also increase the 
duration of the study (due to the staggering of the roll-
out) and will possibly increase the number of clusters 
(and patients) exposed to the intervention (due to all 
clusters receiving the intervention). For these reasons, 
justifying the need to expose all clusters (where this is 
the case) to the intervention is important. The cluster 
crossover design is a more statistically efficient design 
than the SW-CRT and it might therefore be important to 
justify why a unidirectional crossover design has been 
chosen. However, in practice the use of the cluster 
crossover design is restricted to interventions that can 
be withdrawn from use, and this largely depends on 
the type of intervention being evaluated.
Item 2b: Objective
Standard CONSORT item—Specific objectives or 
hypotheses.
CONSORT cluster extension—Whether objectives 
pertain to the cluster level, the individual participant 
level, or both.
Extension for SW-CRTs—Specific objectives or 
hypotheses.
Example—“We report a stepped wedge cluster RCT 
aimed to evaluate the impact of the WHO SSC (World 
Health Organisation Surgical Safety Checklist) on 
morbidity, mortality, and length of hospital stay (LOS). 
We hypothesized a reduction of 30 days’ in-hospital 
morbidity and mortality and subsequent LOS post-
Checklist implementation.”33
Explanation—Having a clear and succinct set of 
objectives can help summarise the overarching aims of 
the study. Specification of the objectives gives clarity 
about the anticipated effects of the intervention being 
evaluated (as in the example). Sometimes these effects 
will be anticipated to be on process outcomes (eg, 
systems changes or clinician performance), particularly 
in trials which target healthcare providers; other times 
the intervention might target patients and anticipate 
effects on clinical outcomes. One specific objective 
which can be of interest in a SW-CRT is to evaluate the 
effect of the intervention by timing of implementation 
(eg, does the effect of the intervention change as the 
intervention is perhaps refined over time) or time since 
intervention implementation (eg, does the intervention 
create a permanent effect). Also of relevance is whether 
the study is to show superiority of the intervention 
condition, non-inferiority, or equivalence. For non-
inferiority or equivalence, authors should also ensure 
reporting according to the CONSORT extension for 
non-inferiority and equivalence studies.41
Methods: Trial design
Item 3a: Trial design
Standard CONSORT item—Description of trial design 
(such as parallel or factorial) including allocation ratio.
CONSORT cluster extension—Definition of cluster 
and description of how the design features apply to the 
clusters.
Extension for SW-CRTs—Description and diagram 
of trial design including definition of cluster, number 
of sequences, number of clusters randomised to each 
sequence, number of periods, duration of time between 
each step, and whether the participants assessed in 
different periods are the same people, different people, 
or a mixture.
Example 1—“During the DAVE study, the intervention 
will be rolled out sequentially to 128 rural villages 
(clusters) over four time periods. The evaluation will 
consist of data collection at five fixed time points 
(baseline and following each of the four intervention 
periods)… The intervention will be fully implemented 
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by the end of the trial, with all 128 villages receiving 
the intervention: 22 first receiving the intervention 
at period 2, 36 at period 3, 35 at period 4, and 35 at 
period 5 (supplementary materials, fig S1).”42
Example 2—“This study will use a closed cohort 
stepped wedge cluster randomised design, which 
involves a sequential crossover of clusters from the 
control to the intervention arm, so that every cluster 
begins in the control condition and eventually receives 
the intervention, with the order of crossover randomly 
determined. The study will be conducted in four rural 
villages…At the start of the study period, baseline (T0) 
demographic and health data will be collected from 
each consenting household and baseline hygiene 
education will be provided. …The second (T1) health 
survey will start 4 weeks after the initiation of piped 
untreated river water supply to evaluate the impact 
of hygiene education combined with improved water 
quantity compared with baseline (T0). RBF-treated 
water (intervention arm) will then be sequentially 
introduced to each village in random order at 12-week 
intervals (T2–T5), with health surveys performed 
4 weeks after the implementation of the intervention 
to assess the additional effects of improved water 
quality.”43
Explanation—The specific details of the design of 
the SW-CRT have implications for numerous parts of 
reporting, including the type of analysis and sample 
size calculations required.
Information on the number of sequences and the 
number of clusters randomised to each sequence is the 
core of the study design and so should be reported. The 
number of time periods will often (but not always) be 
one more than the number of steps (as in example 1). 
Definition of cluster (as clearly reported in example 1) 
and duration of periods are also crucial. The duration 
of the first and last periods can sometimes differ from 
other periods; if so, this should be reported. The 
number of clusters allocated to each sequence may 
vary and, if so, this should be reported.
Information on whether the measurements taken in 
the different periods are from the same individuals or 
different individuals is important for both sample size 
and analysis. In an open cohort design, participants 
are repeatedly assessed over a series of measurement 
points and participants can join and leave the cohort; 
in a closed cohort design, new participants cannot 
join the study; in a cross-sectional design, different 
participants are assessed at each measurement 
occasion. Measurements can also take place at one 
point in time in each period, or can be continuous 
throughout the period. This issue is covered in more 
detail under item 6a (assessments of outcomes).
A diagram of the trial design can efficiently 
communicate the details. Key points to depict in the 
design diagram are the timing of the interventions 
(item 3a) and the timing of the data collection (item 
6a). In the Riverbank Filtration Trial, key information 
about the design was reported in a diagram (see fig 2) 
and the main text (example 2).
Item 3b: Changes to trial design
Standard CONSORT item—Important changes to 
methods after trial commencement (such as eligibility 
criteria), with reasons.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Important changes to 
methods after trial commencement (such as eligibility 
criteria), with reasons.
Example—“…delayed Research and Development 
registration shortened the baseline pre-randomisation 
phase from twelve months to nine in the first hospitals 
randomised to the intervention.”34
Explanation—Changes to key features of the design 
can have important implications for the interpretation 
of results. Some changes or deviations may be 
inevitable. Potential changes in the SW-CRT include 
modification to the duration between steps (perhaps 
because of study set up delays as in the example). The 
timing of any changes is important as they may affect 
some observations or clusters and not others.
Methods: Participants
Item 4a: Participants
Standard CONSORT item—Eligibility criteria for 
participants.
CONSORT cluster extension—Eligibility criteria for 
clusters.
Figure 2. Stepped wedge schematic for the study. Each cell represents a data collection point. 
Each ‘step’ from T1 to T5 will be ~12 weeks in length. Shaded red cells represent the prepipe 
augmentation stage and the baseline (T0) survey will be performed during this stage. Once the 
augmented pipework has been completed in all four villages, piped untreated river water will 
be delivered to all villages (unshaded cells, pre-riverbank filtration (RBF) intervention). The RBF
 intervention (shaded blue cells) will then be sequentially introduced to the villages in random 
order. The T1–T5 household surveys will start in week 5 of each step.
Fig 2 | Example of a diagram of a stepped wedge cluster randomised trial (SW-CRT) 
from the Riverbank Filtration Trial. Adapted from figure 2 in McGuinness SL, O’Toole 
JE, Boving TB, et al. Protocol for a cluster randomised stepped wedge trial assessing 
the impact of a community-level hygiene intervention and a water intervention 
using riverbank filtration technology on diarrhoeal prevalence in India. BMJ Open 
2017;7:e015036. doi: 10.1136/bmjopen-2016-015036. PubMed PMID: 28314746; 
PubMed Central PMCID: PMC5372111.
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Extension for SW-CRTs—Eligibility criteria for 
clusters and participants.
Example—“Inclusion criteria: Institution level: 
At least two units of one (from each) nursing home 
must participate in the study, from which at least 30 
residents with dementia can be recruited. The care of 
the residents must predominantly take place in the 
respective unit. Resident level: Criteria for inclusion 
are informed consent obtained from people with 
dementia or their legal representative; diagnosis of 
dementia based on the medical diagnosis in the charts 
and a FAST score > 1); residence for at least 14 days in 
the unit. Staff level: All of the nursing staff working in 
one of the two participating wards of the nursing home 
must provide their informed consent.”44
Explanation—The SW-CRT is a type of cluster 
randomised trial and as such, has inclusion and 
exclusion criteria for both clusters and participants. 
Furthermore, there may be multiple levels of 
participants. For example, clusters may be general 
practices that include cluster-level participants (eg, 
general practitioners) and individual-level participants 
(eg, patients). So, in some trials, there may be multiple 
levels at which inclusion and exclusion criteria apply 
(as in the example). Reporting of eligibility criteria 
is important so that readers can infer how typical 
or atypical the clusters and participants are of the 
population at large.45
Item 4b: Setting
Standard CONSORT item—Settings and locations where 
the data were collected.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Settings and locations 
where the data were collected.
Readers are referred to the CONSORT statement and 
its extension to CRTs for examples and explanation.3 5
Methods: Intervention
Item 5: Intervention
Standard CONSORT item—The interventions for each 
group with sufficient details to allow replication, 
including how and when they were administered.
CONSORT cluster extension—Whether interventions 
pertain to the cluster level, the individual participant 
level, or both.
Extension for SW-CRTs—The intervention and control 
conditions with sufficient details to allow replication, 
including whether the intervention was maintained or 
repeated, and whether it was delivered at the cluster 
level, the individual participant level, or both.
Example 1 (Description of the intervention 
condition)—“The intervention involves three key 
modes of delivery: verbally via reception staff, in paper 
form with a pamphlet, and electronically via a secure, 
internet-enabled tablet (see Table (not provided) for 
overview of intervention). First, reception staff will 
verify the organ donor registration status of patients 
upon their arrival at the clinic on the provincial health 
card that patients must provide to receive healthcare 
services from their family physician. As reception 
staff already request a patient’s health card during 
their visit, this step is designed to fit within existing 
work routines rather than increasing any workload. 
Reception staff will provide patients that have not yet 
registered with an educational pamphlet including 
a photo and signature of the physicians in the office 
and office logos and include messages that directly 
address identified barriers to donor registration. 
Second, internet-enabled tablets will be provided 
in each waiting room to give patients the immediate 
opportunity to register for organ donation online via a 
secure provincial website. The location of the materials 
will be tailored according to the family physician 
office’s preferences.”46
Example 2 (Description of control condition)—“If 
the participant’s medical centre is in the control 
phase, they will receive usual care. In Australia, 
usual care would mean the patient would consult 
their GP as per normal standards for that practice for 
a patient discharged from hospital. There will be no 
pharmacist in the medical centre during the control 
phase. Medication liaison in the form of a discharge 
medication record may be provided to patients on 
discharge from hospital and may be included in the 
hospital discharge summary to the GP.”47
Example 3 (Unit of delivery is individual)—“The 
intervention comprised a therapeutic dose of AQ (10 
mg/kg/day for 3 days) combined with one dose of SP on 
the first day (25mg sulfamethoxypirazyne and 1.25mg 
pyrimethamine per kg in 2008, 25mg sulfadoxine, 
1.25mg pyrimethamine in 2009–10) administered 
once per month for the last three months of the malaria 
transmission season (September-November).”48
Example 4 (Continuously delivered intervention)—“It 
(the intervention) comprised bedside placement of 
alcohol hand-rub, posters and patient empowerment 
materials encouraging healthcare workers to clean 
their hands, plus audit and feedback of hand-hygiene 
compliance at least once every 6 months.”34
Explanation—Clear reporting of the intervention is 
essential to allow replication and implementation of 
successful interventions (example 1). For interventions 
demonstrated to have little evidence of benefit, 
reporting of sufficient detail of the intervention helps 
to avoid evaluating the same intervention again or 
to identify what aspects of the intervention could be 
modified. This is especially important for complex 
interventions, a common type of intervention evaluated 
in SW-CRTs. We recommend reporting details of the 
intervention as per the template for intervention 
description and replication guideline.49 In accordance 
with the original CONSORT statement, it is important 
to describe all treatment conditions being compared. 
In SW-CRTs the comparator is often usual care which 
should be described in sufficient detail (example 2). 
The control condition should be described in a similar 
level of detail to the intervention condition.45
Information on whether the intervention is delivered 
at the cluster level or individual level (or perhaps both) 
is important as it allows identification of whether 
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individuals can avoid the intervention. For example, 
an intervention which is delivered at the cluster level 
will often mean that it is delivered to all individuals 
within that cluster (example 1). In the SMC Trial, the 
intervention was delivered directly to the individual 
(example 3). This information is also important as it 
can inform the degree of penetration of the intervention 
and it can also be helpful in eliciting what consent 
procedures should be in place (items 10c and 26).
In a SW-CRT it is important to be clear about whether 
the intervention is expected to create an effect that is 
expected to be immediate (or delayed); and whether 
the anticipated effects of the intervention are expected 
to be sustained. This is important because the 
observations contributing to the analysis will consist of 
a mixture of observations collected immediately after 
roll-out of the intervention; and observations collected 
sometime after roll-out.
In some SW-CRTs the exact form of the intervention 
may evolve over time; reporting this information 
allows assessment of the level of standardisation of the 
intervention across the clusters.45
In example 1, the intervention being evaluated is 
formed of several components. Depending on the 
exact nature of the intervention, there may be a delay 
before any anticipated effect is realised. The effects of 
some components may also wane through familiarity. 
Furthermore, some components of an intervention 
might be continuously delivered (ie, provision of 
pamphlets) whereas some components might be 
delivered just once (ie, educational components). 
In example 4, the educational component of the 
intervention is repeated and so its anticipated effect is 
less likely to decay.
Methods: Outcomes
Item 6a: Outcomes
Standard CONSORT item—Completely defined 
prespecified primary and secondary outcome 
measures, including how and when they were assessed.
CONSORT cluster extension—Whether outcome 
measures pertain to the cluster level, the individual 
participant level or both.
Extension for SW-CRTs—Completely defined 
prespecified primary and secondary outcome 
measures, including how and when they were assessed.
Example 1 (Prespecified outcomes)—“The primary 
outcome of the study is a 7-day period prevalence 
of diarrhoea among villagers of all ages. Secondary 
outcomes include a 7-day period prevalence of 
other hygiene-related illnesses (respiratory and skin 
infections), reported changes in hygiene practices, 
household water usage and water supply preference.”43
Example 2 (Cross-sectional sampling)—“Data 
collection for the evaluation took the form of a postal 
survey conducted at five fixed time points: baseline 
(in the month prior to commencement of the first 
intervention period) and within a week of the end of 
each of the four intervention periods. A repeated cross-
sectional design was employed, in which a random 
sample of households within each cluster was selected 
to receive the survey at each period.”28
Example 3 (Cohort design)—“All household members 
will be eligible for inclusion in the study, regardless 
of age. …Each household will have the option to 
participate in up to five subsequent surveys…Outcomes 
will be measured at each of the six survey visits.”43
Example 4 (Transition period)—“A 1-month 
transition phase is included where the medical centre 
is not considered as being in control or intervention and 
does not contribute to analysis. This transition period 
allows for the time it takes to embed the intervention 
into a medical centre.”47
Example 5 (Time to assessment and source of 
data)—“Participants will be followed up to 12 months 
from day of hospital discharge. This will be done 
through collection of routine data from the hospital 
and medical centre. Demographics and reason for 
admission at enrolment and subsequent admissions 
in the 12-month follow-up will be collected through 
participant hospital records…Medical centre records 
will be used to identify whether a discharge treatment 
plan was received and the timeliness and number of 
GP visits during the 12-month follow-up period for 
each participant.”47
Explanation—All outcomes should be completely 
defined. This should include the prespecified primary 
outcome and all secondary outcome measures 
(example 1). It is also important to report clearly how 
and when these measurements were obtained.
SW-CRTs make a series of measurements over time 
within each cluster. These measurements could be on 
different participants in each period (ie, cross-sectional 
design) as in example 2; the same participants (ie, 
cohort design) as in example 3; or a mixture, and this 
will inform the method of analysis and has implications 
for sample size calculations. Data are rarely collected 
at the level of the cluster, but knowledge of whether 
outcomes in each period are at the cluster level (either 
because of true cluster level outcomes or because of the 
availability of aggregated data only) or individual level 
has implications for the method of analysis.
It should be reported whether outcomes are collected 
at discrete points in time common to all participants 
(eg, a survey implemented at several discrete points in 
time as in example 3), or at time points specific to each 
participant (eg, as they leave hospital as in example 
5). The timing of measurements has implications for 
the choice of analysis. For example, if the outcomes 
are collected at discrete time points (as in example 3), 
then time effects can be included as categorical effects; 
whereas if the outcomes are collected continuously (eg, 
as would be the case in a SW-CRT where the outcome 
was routinely collected mortality data), then time 
effects could potentially be modelled using parametric 
or semi-parametric forms.
The reporting of the timing of data collection 
should also note whether there were periods in which 
outcomes were not ascertained, for example transition 
periods immediately after the intervention was rolled 
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out, to allow time for the intervention to realise its full 
impact (as in example 4).
In individually and cluster randomised parallel 
trials outcomes are often assessed at multiple time 
points (eg, 6 and 12 months after randomisation) 
and it is important to prespecify the primary follow-
up time of interest. This might also be the case in 
SW-CRTs. Sometimes the outcome assessments will 
extend beyond the actual study dates. For example, a 
trial might roll-out the intervention to clusters over a 
four year period and the primary follow-up time might 
be 30 years later.50 Clear reporting on the timing of 
follow-up assessments (as in example 5) also allows 
assessment of whether all observations collected 
under the intervention condition were fully exposed 
to the intervention, and whether any observations 
collected under the control condition might have been 
contaminated by the intervention.
Reporting whether data were collected from routine 
sources or purposively collected can help ascertain the 
risk of bias (eg, from measurement of the outcome) and 
identify who are the human research participants (see 
item 26). SW-CRTs are often implemented in real world 
settings and, as such, may rely on routinely collected 
outcome data (example 5). Reporting of whether 
the data collection procedures changed over time is 
important given the imbalance over time with respect 
to intervention conditions.51 It is also important to 
report any measures which can allow assessment of 
the reliability and validity of routinely collected data.
Item 6b: Changes to outcomes
Standard CONSORT item—Any changes to trial 
outcomes after the trial commenced, with reasons.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Any changes to trial 
outcomes after the trial commenced, with reasons.
Readers are referred to the CONSORT statement and 
the extension to the CONSORT statement for examples 
and explanation.3 5
Methods: Sample size
Item 7a: Sample size
Standard CONSORT item—How sample size was 
determined.
CONSORT cluster extension—Method of calculation, 
number of clusters (and whether equal or unequal 
cluster sizes are assumed), cluster size, a coefficient of 
intracluster correlation (ICC or k), and an indication of 
its uncertainty.
Extension for SW-CRTs—How sample size was 
determined. Method of calculation and relevant 
parameters with sufficient detail so the calculation can 
be replicated. Assumptions made about correlations 
between outcomes of participants from the same 
cluster (table 5).
Example 1 (Sample size)—“We would consider 
an absolute increase of 10% in the proportion of 
patients who are registered organ donors at 7 days 
post-encounter to be both clinically important and 
Table 5 | Essential and additional information to report under sample size calculation (item 7a)
Information for reporting Further explanation
Essential
Level of significance State whether a one or two-sided test was used.
Power
Target difference
Variation of outcome For continuous variables this will be a standard deviation. For binary variables this will be the control 
 proportion.
Number of clusters There should be clarity between the total number of clusters and the number of clusters allocated to each 
sequence. A diagram can be helpful.
Number of sequences
Average cluster size There should be clarity between cluster size per measurement period and total cluster size.
The assumed correlation 
structure
The assumed intracluster correlation coefficient (ICC) and whether the ICC is time dependent or time 
 independent. If time dependent, state the parameters that were assumed to accommodate the time 
 dependency, for example, the within period ICC and the between period ICC or the cluster autocorrelation 
coefficient, or any variance components. For binary outcomes it is important to report the scale of the 
 correlations or variance components (eg, proportions scale or logistic scale). For rate outcomes it might be 
more appropriate to report coefficient of variations of outcomes. 
Within person correlations Where the design includes repeated measurements on the same individual, describe the assumed  correlation 
structure at the individual level, including if any decay in correlation in repeated measures on the same 
 individual has been accounted for (eg, an individual autocorrelation coefficient).
Additional
Method used Reference to the methodology used and statistical packages (including details of functions) used for 
 implementation.
Allowance for variation in 
cluster size
Whether variation in cluster sizes were accommodated and how. This can include variation in total cluster 
sizes or variation in cluster-period sizes.
Allowance for attrition This can include attrition both at the cluster level and the individual level. If included, provide an explanation 
of how this was allowed for.
Number of clusters per 
sequence
If an unequal number of clusters per sequence was used, include information on whether this was accounted 
for in the sample size calculation.
Allowance for transition 
periods
State whether any transition periods were allowed for and how. This includes a description of the duration of 
the transition period and whether these data were excluded from the sample size calculation, or included with 
alternative coding of the intervention indicator
Sensitivity analysis This can include sensitivity to all parameters which might vary in the actual trial. A justification should be 
provided for all assumed sample size parameters.
 o
n
 29 Novem
ber 2018 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k1614 on 9 November 2018. Downloaded from 
RESEARCH METHODS AND REPORTING
12 doi: 10.1136/bmj.k1614 | BMJ 2018;363:k1614 | the bmj
feasible. Our sample size of 6 clusters (10,500 patients 
in total) achieves 80% power to detect this difference 
assuming a control proportion of 0.5 using a two-sided 
test at the 5% level of significance.(33) Our calculation 
assumes an intra cluster correlation coefficient of 0.06, 
as calculated from our previous work (19), an average 
of 250 patient encounters per site in each two-week 
interval, and a cluster autocorrelation coefficient 
of 0.8 to allow for a 20% decay in the strength of 
the correlation in repeated measures over time.(20) 
The percentage of registered donors in the control 
condition is conservatively assumed to be 50% to 
allow for a higher prevalence of registered donors in 
our participating offices than the provincial average. 
No adjustment is made for cluster attrition as the risk 
of attrition is low, and all outcomes will be assessed 
from routinely collected sources, regardless of any 
drop-out. Given some uncertainty around parameter 
estimates required for the stepped wedge sample size 
calculation, sensitivity of our detectable effect size 
to a range of alternative assumptions is presented 
in Table (not shown). The results show that across 
a range of control arm proportions (from 0.4 to 0.5), 
average cluster sizes (from 100 to 400), and cluster 
autocorrelation coefficients (from 0.8 to 0.95), our 
sample size of 6 practices will achieve 80% power to 
detect absolute increases between 5% and 11%.”46
Example 2 (Sample size fixed by design)—“The study 
had a fixed sample size by design that could not be 
modified, so the power calculations did not inform any 
sample size targets.”52
Explanation—The method of calculation and 
all relevant parameters, used in the sample size 
calculation should be given (including allowance for 
any small sample corrections). Most of the key items to 
report are listed in table 5. These have been divided into 
key items which are essential and likely of relevance 
to all SW-CRTs; and those which might be considered 
additional or supplementary information which will 
only be of relevance to some SW-CRTs. Besides the 
usual effect size, significance level, and power, these 
may include: the cluster size and whether account of 
unequal cluster sizes has been made, avoiding any 
ambiguity between cluster size per measurement 
period and total cluster size; a within period ICC and 
assumptions about correlations between outcomes 
of different participants from the same cluster in 
different periods (or other assumptions which 
appropriately reflect the complexity of the design); 
and allowance for repeated measurement taken from 
the same participants, with sufficient detail to allow 
the calculation to be replicated. Often a sensitivity 
analysis, looking at the effect of relaxing some of the 
assumptions, may be warranted. Reporting of these 
basic sample size elements is poor in SW-CRTs;8 as is 
the reporting of basic elements in parallel CRTs.53
Specifying the method of sample size calculation,12 54 
or providing access to sample size calculation code or 
programmed sample size function can aid replication 
of the sample size (example 1 reported they used the 
Hooper method).12  37  55  56 Detailed reporting of the 
sample size method will allow assessment of whether 
the method has allowed for all features inherent to 
the particular design (eg, transition periods, repeated 
measures on the same participants).
For clarity it is important to distinguish between 
total cluster size (across all periods) and cluster sizes 
per period (example 1). In a design which repeatedly 
measures the same participants it would be natural to 
provide the number of participants in each cluster and 
the number of repeated measurements per participant; 
in a design which involves taking repeated, discrete 
samples with different participants each time it would 
be natural to provide the number of participants in 
each cluster in each of these periods; whereas in a 
design where newly eligible individuals are recruited 
continuously it might be more appropriate to report the 
total number of participants expected in each cluster 
over the duration of recruitment.
In a parallel CRT it is important to report the ICC 
(the correlation between outcomes of two individuals 
from the same cluster). The coefficient of variation of 
cluster rates, proportions or means has been suggested 
as an alternative parameter in sample size formulae for 
CRTs.57 Correlation structures are more complicated 
in a SW-CRT and there may not be a single ICC, as 
the strength of correlation might depend additionally 
on the separation in time.13  21  58 Such correlation 
structures could be formalised in a variety of ways, 
for example using a within period ICC and a between 
period ICC or cluster autocorrelation coefficient (as in 
example 1).13 In SW-CRTs where the same individuals 
are assessed repeatedly it may also be important to 
consider correlations over time within individuals.12
An indication of the sensitivity of the sample size 
or power to the assumed parameter values could be 
provided, for example, by reporting sample size or 
power at a variety of alternative correlation values. 
Rationale for the assumed parameter values should be 
provided (as in example 1).
In CRTs the sample size (and so consequently the 
number of clusters) is often based on the number 
needed to detect the target difference at a desired level 
of power and significance.59 SW-CRTs can sometimes 
have their sample size fixed by the number of clusters, 
participants, or both, available in a natural setting. 
Whether the sample size was fixed by factors outside 
of the control of the experimenters or based on the 
target difference (as conventionally is the case in a 
randomised controlled trial) should be reported (as in 
example 2). When the sample size is fixed, it can be 
useful to report what effect size the study was powered 
to detect. If no power calculation was performed, this 
should be reported. Retrospective power calculations 
based on the results of the trial are of little merit.3 60
Item 7b: Interim analyses
Standard CONSORT item—When applicable, 
explanation of any interim analyses and stopping 
guidelines.
CONSORT cluster extension—No modification 
suggested.
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Extension for SW-CRTs—When applicable, 
explanation of any interim analyses and stopping 
guidelines.
Explanation—Interim analyses of outcomes can 
be used to assess harm, futility, and efficacy. Interim 
analyses can also be used to monitor recruitment and 
retention rates, and monitor balance across control and 
intervention conditions (where trial processes suggest 
that there may be a risk of differential recruitment or 
consent).
The relevance of interim analyses of outcomes might 
be questionable in some SW-CRTs, so careful reporting 
of motivation is important. For example, if the 
intervention is being rolled out to all clusters within 
the fastest time frame possible, then stopping the trial 
early after demonstrating efficacy does not necessarily 
mean the intervention can be rolled out to the 
remaining clusters immediately. In some settings, SW-
CRTs evaluate interventions for which safety concerns 
are likely to be minimal (although this will not always 
be the case). It might be of interest to consider stopping 
a SW-CRT for futility, although if there are minimal 
safety concerns then stopping the trial early for futility 
may also not be worthwhile. However, other important 
reasons for considering stopping a trial include that the 
trial itself is not successful, perhaps because clusters 
are failing to adhere to the randomisation schedule, 
because data for outcomes are not forthcoming, or 
because procedural requirements have delayed the 
start dates for many clusters.61 Dates or times at 
which any interim analysis will be carried out should 
be reported together with objectives of such interim 
analyses.
Of note, in a SW-CRT due to the imbalanced nature 
of the design, interim analyses for outcomes carried 
out early in the trial will have a large imbalance 
between numbers of observations exposed to control 
and intervention conditions. This imbalance is likely 
to have power implications;18 and will make a blinded 
interim analysis infeasible. The clustered nature of the 
data will also have implications on power and interim 
analyses.62 Proposed methods of interim analysis 
should be outlined. Interim analyses of outcomes 
might or might not follow the same method of analysis 
planned for the main results. As with any trial, 
incorporation of any interim analyses of outcomes 
(where a decision is to be made about continuation of 
the trial) should be allowed for in power calculations 
to control for the overall Type I error rate.
Methods: Randomisation
Item 8a: Sequence generation
Standard CONSORT item—Method used to generate the 
random allocation sequence.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Method used to generate the 
random allocation to the sequences of treatments.
Example—“Eligible schools were randomly 
assigned to one of the four sequences (3 or 4 schools 
per sequence) for time of crossover from control 
to intervention using a computer-generated list of 
random numbers.”63
Explanation—Random allocation in SW-CRTs takes a 
different form to that in parallel arm designs. Rather 
than each cluster being randomly allocated to one of 
two treatments, allocation is to one of several sequences 
which define the order with which clusters cross from 
the control condition to the intervention condition (the 
example). The term “sequence generation” in a SW-
CRT therefore has a slightly different meaning to that 
of individually randomised trials. In an individually 
randomised trial “sequence” refers to a sequence of 
treatments to allocate all participants to either the 
intervention or control condition.
Furthermore, rather than the randomisation being 
performed as clusters or individuals present to the trial 
the randomisation in a SW-CRT is usually done at a 
single point in time before the trial starts.
Item 8b: Randomisation method
Standard CONSORT—Type of randomisation; details of 
any restriction (such as blocking and block size).
CONSORT cluster extension—Details of stratification 
or matching if used.
Extension for SW-CRTs—Type of randomisation; 
details of any constrained randomisation or 
stratification if used.
Example 1 (Unrestricted)—“Nursing-home units 
were the unit of randomisation... RL (not involved in 
recruitment) randomly allocated units to one of five 
groups with computer-generated random numbers…”64
Example 2 (Stratification)—“All schools are assigned 
a decile rating, which indicates the extent to which the 
school draws its students from a range of socioeconomic 
areas. Decile 1 schools are the 10% of schools with the 
highest proportion of students from low socioeconomic 
resource areas (defined according to residents’ 
income, occupation, household crowding, educational 
qualifications and income support) and decile 10 are 
the 10% of schools with the highest proportion of 
students from high socioeconomic areas…. The order 
of switch-over is determined randomly for each group 
(decile) of clusters.”65
Example 3 (Covariate constrained randomisation)—
“The randomization was conducted using a highly 
restricted randomization design. With this limited 
number of randomization units, selection of one 
sequence from the 5.4 *1026 completely at random 
would run the risk of obtaining a sequence that is 
substantially unbalanced with respect to one or more 
potentially important covariates. Randomization was 
done using a highly restricted randomization design 
to achieve close balance with respect to clinic-level 
covariates including mean CD4 count, clinic size, 
average education, tuberculosis treatment levels, 
existence of a supervised tuberculosis therapy (DOTS) 
program and geography (reference cited to detailed 
methods).”66
Explanation—In a SW-CRT, rather than the 
randomisations being done sequentially (as the patient 
or cluster presents to the trial), the randomisation is 
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usually done at a single point in time before the trial 
starts. This means that different methods for controlling 
the balance of cluster level factors can be considered 
along with methods used in individually randomised 
trials such as stratification.67 How the randomisation 
is restricted is known to have implications for analysis.
There are two common ways in which clusters may 
be allocated in a SW-CRT. One is simple unrestricted 
allocation to one of several possible sequences (example 
1); another is stratified allocation with clusters divided 
into distinct strata before random allocation within 
each stratum (example 2). For a stratified design, the 
sequences are generated independently within each 
stratum. This essentially means that separate mini SW-
CRTs are conducted in each stratum (example 2). Yet 
another method of allocation is covariate constrained 
allocation which balances key covariate values (such 
as cluster size) between intervention and control 
conditions (example 3).66
Item 9: Allocation concealment
Standard CONSORT item—Mechanism used to 
implement the random allocation sequence (such as 
sequentially numbered containers), describing any 
steps taken to conceal the sequence until interventions 
were assigned.
CONSORT cluster extension—Specification that 
allocation was based on clusters rather than individuals 
and whether allocation concealment (if any) was at the 
cluster level, the individual participant level, or both.
Extension for SW-CRTs—Specification that allocation 
was based on clusters; description of any methods 
used to conceal the allocation from the clusters until 
after recruitment.
Example 1 (Concealment from cluster)—“Once 14 
medical centres have provided consent to be involved 
in the study, each enrolled medical centre will be 
randomised to a transition step.”47
Example 2 (Concealment of crossover date)—“The 
allocation sequence will only be made available to 
two study investigators (ABF and MS). Indian study 
investigators will be blinded to the allocation sequence 
with only the next village randomised for rollout 
being revealed at each intervention implementation 
time point. Study participants will be blinded to the 
allocation sequence and those not yet receiving the 
intervention will not be aware of the time at which they 
will have the intervention implemented.”43
Explanation—In a SW-CRT, clusters are allocated to a 
sequence of treatments, so clusters will spend time in 
the control condition until a particular date when they 
cross to the intervention condition. This is unlike a 
parallel arm cluster randomised trial in which clusters 
are allocated to treatment conditions. Randomisation 
of all clusters (to sequences) in a SW-CRT will often 
occur at a single point in time (as in example 1). 
Randomisation could, in theory, also be performed 
at step-times, where one or more of the remaining 
clusters will be randomly selected to cross over just 
before the crossover date (no examples of this have 
been identified).
It is important to report any method that was used 
to conceal the allocation from clusters and from those 
individuals responsible for recruiting clusters, until 
after recruitment. Reporting of this information allows 
assessment of the potential for selection bias.68 One 
common way of preserving allocation concealment is 
to perform the randomisation after recruitment of all 
clusters (as in example 1).
When randomisation of the clusters occurs at a 
single point, the crossover date may be revealed 
immediately to each cluster, or revealed sequentially 
to the clusters as they approach the time of crossover 
(as in example 2). Reporting when clusters were told 
of their crossover date allows assessment of potential 
biases. For example, when clusters are informed of 
their date of crossover at the beginning of the trial, 
some clusters (eg, those randomised to cross over 
later) may drop out, leading to differential attrition; 
yet at the same time a public randomisation at the 
start of the trial may also prevent subversion of the 
randomisation process.68 Knowledge of when a 
cluster is crossing over could lead to other biases, for 
example, if individuals within a cluster are aware of 
the impending crossover, they may defer enrolling 
participants into the trial to ensure they receive the 
intervention.
Full transparency of reporting of the blinding 
throughout the trial, including the randomisation 
process, is best reported using a timeline diagram.69
Methods: Implementation of randomisation
As with a parallel CRT, it is important that all steps in 
the implementation of the randomisation process are 
clearly described. It is important that this information 
on the allocation and recruitment process is described 
for both clusters and participants. Information on the 
allocation and enrolment of the clusters is described 
in item 10a and corresponding information for 
participants in item 10b. Enrolment of participants is 
closely linked to the consent process (eg, differential 
consent processes can have implications for selective 
recruitment). Therefore, following the cluster 
CONSORT extension, item 10c describes the consent 
processes.
Of note, we use the term “selection bias” to 
refer to any process by which there is differential 
inclusion of participants in the treatment conditions 
being compared. Sometimes selection bias is used 
to refer only to differential inclusion of clusters 
by intervention conditions. More specifically, 
“identification bias” refers to biases which are 
induced by differential application of the inclusion 
or exclusion criteria.68 The term “recruitment bias” 
refers to biases which are induced by differential 
recruitment into the trial by the healthcare 
practitioner or to biases induced by individuals 
differentially declining to participate.
Item 10a: Inclusion of clusters
Standard CONSORT item—Not included in original 
CONSORT statement.
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CONSORT cluster extension—Who generated the 
random allocation sequence, who enrolled clusters, 
and who assigned clusters to interventions.
Extension for SW-CRTs—Who generated the 
randomisation schedule, who enrolled clusters, and 
who assigned clusters to sequences.
Example—“We will recruit a convenience sample 
of practices from within our network of family 
physician office contacts within the London, Ontario 
and Stratford, Ontario communities. A collaborating 
family physician will send an introductory email to 
potential family physician contacts, inviting them and 
their practice to consider participating. We will then 
arrange an in-person meeting with family physicians 
from interested sites to introduce our study and 
obtain written agreement from family physicians and 
offices agreeing to participate that meet our eligibility 
criteria. A statistician blinded to cluster identity and 
not involved in the intervention delivery will generate 
the allocation sequence using computer-generated 
random numbers.”46
Explanation—Knowledge of who implemented the 
randomisation procedures at the level of the cluster 
is required for ascertaining if selection biases are 
possible.
It is important to have a separation of roles between 
those who generate the randomisation schedule 
and those who recruit, enrol, and assign clusters to 
the sequence (as in the example). If the person who 
generated the randomisation was also responsible for 
recruiting the clusters, this could mean that there was 
an increased risk of selection bias. This is best achieved 
by having a person independent of the trial doing the 
randomisation. This will be less important in trials 
where the randomisation takes place after recruitment 
of all clusters.
Item 10b: Inclusion of participants
Standard CONSORT item—Not included in original 
CONSORT statement.
CONSORT cluster extension—Mechanism by which 
individual participants were included in clusters for the 
purposes of the trial (such as complete enumeration, 
random sampling).
Extension for SW-CRTs—Mechanism by which 
individual participants were included in clusters for the 
purposes of the trial (such as complete enumeration 
or random sampling; continuous recruitment or 
ascertainment; or recruitment at a fixed point in time), 
including who recruited or identified participants.
Example 1 (Complete enumeration with continuous 
ascertainment)—“The study included all patients 
admitted to 16 acute adult wards of one general 
hospital over a 32-week period.”70
Example 2 (Random sampling)—“Data collection for 
the evaluation study will focus on adults aged 18 years 
and over. The study will use a repeated cross-sectional 
design, in which a random sample of people within 
each cluster will be surveyed at each stage. A complete 
list of all households in each of the 128 study villages 
will be obtained using the Postcode... The order in 
which households are approached to participate in the 
survey at each stage will be randomly generated...One 
adult per household will be randomly selected.”42
Example 3 (Continuous recruitment)—“Then, the 
leaders of the nursing homes are responsible for the 
recruitment of the units and the residents according to 
the inclusion and exclusion criteria of the study. Here, 
all eligible participants of the participating units are 
invited to participate. Before the recruitment procedure 
will commence, each leader of the nursing homes will 
attend a kick-off meeting held by a senior investigator 
about the inclusion and exclusion criteria and the 
planned recruitment strategy. For the participants who 
drop out of the trial, we are planning to monitor the 
reasons (eg, death or moving) and perform a sensitivity 
analysis at the end of the trial to determine whether 
they differ according to certain characteristics (eg, the 
prevalence of the challenging behavior or gender). 
Residents who are newly admitted to clusters during 
follow up will also be included in the study …”44
Explanation—Individual participants can be 
included in a SW-CRT in many different ways. 
Sometimes, participants are not recruited into a trial, 
but rather their data are used from routinely collected 
sources (example 1). In this case it is common to take 
a complete enumeration of the cluster or at least those 
meeting the eligibility criteria. Alternatively, a sample 
of individuals from the cluster might be asked to 
complete data assessments or questionnaires in each 
period (example 2). Alternatively, participants might 
be recruited to participate in the trial. This recruitment 
might take place continuously (example 3) or at a fixed 
point in time before the start of the trial.
Knowledge of how participants are included in the 
trial can help assess the likelihood of identification and 
recruitment bias. Trials with complete enumerations 
are less likely to suffer from these biases (example 1). 
Where participants are identified or recruited after 
randomisation, either a complete enumeration of the 
cluster or recruitment or identification by someone 
who is blind to allocation can help mitigate recruitment 
and identification biases. Therefore, clear reporting of 
who recruited or identified participants and whether 
or not such individuals were blind to allocation is 
important so readers can determine the risks for bias. 
Identification and recruitment biases will not occur 
in designs in which participants are recruited before 
randomisation.
Item 10c: Consent
Standard CONSORT item—Not included in original 
CONSORT statement.
CONSORT cluster extension—From whom consent 
was sought (representatives of the cluster, or individual 
cluster members, or both), and whether consent was 
sought before or after randomisation.
Extension for SW-CRTs—Whether, from whom and 
when consent was sought and for what; whether this 
differed between treatment conditions.
Example 1 (Individual level consent)—“Written 
informed assent was obtained from all participating 
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children as well as parental consent. Only children 
who provided both assent and parental consent were 
eligible to take part.”63
Example 2 (Cluster and individual level consent)—
“Criteria for inclusion are informed consent 
obtained from people with dementia or their legal 
representative.…All of the nursing staff working in one 
of the two participating wards of the nursing home 
must provide their informed consent.”44
Explanation—Obtaining informed consent 
for participation, study interventions, and data 
collection procedures in clinical trials is an integral 
principle of research ethics and international human 
rights law.71  72 The process by which consent was 
obtained can lead to biases.5 It is important to 
describe what consent was for (eg, exposure to the 
intervention or use of data), whether consent was 
sought before or after randomisation, and whether 
the type of consent differed between intervention and 
control conditions.
In SW-CRTs there can be cluster level research 
participants (eg, healthcare practitioners) and 
individual level research participants (eg, patients).73 
It is therefore important to identify explicitly from 
whom consent was obtained in the study (example 2) 
or to state that consent was not obtained. Furthermore, 
in most cluster trials someone provides access to the 
cluster; such individuals are often called “gatekeepers” 
or “cluster guardians.”74 Gatekeeper permission for 
trial participation is different to consent from cluster 
level research participants, such as healthcare 
providers, for their own participation in the study.
In CRTs in which the treatment is delivered at the 
level of the cluster, it may not be possible to obtain 
consent for exposure to the intervention or control 
condition as the intervention may be impossible to 
avoid (as would be the case in example 1 under item 
10b); however, consent can still be taken for use of data 
(implied by return of questionnaire data in example 2 
under item 10b). It is therefore important to clearly 
report what consent was for. If participants recruited 
to the control and intervention conditions are given 
different information when their consent is taken, this 
can lead to bias.75 The information provided about the 
objectives of the study can itself prompt participants 
to act differently. For example, participants enrolled 
in a study of an intervention to increase uptake of HIV 
screening, who are fully informed about the objectives 
of the study, might increase uptake of screening 
irrespective of allocation to the intervention condition. 
This is known as the Hawthorne effect.76 Reporting 
what information was provided to participants can 
allow readers to judge the risks of such biases. A recent 
systematic review found that of the small number of 
SW-CRTs that reported whether or not consent was 
obtained, only a small proportion reported explicitly 
what this consent was for, and none reported when the 
consent was taken.19
Sometimes a research ethics committee might 
deem it appropriate that the study proceed without 
the informed consent of research participants 
(ie, a waiver of consent) or the research ethics 
committee may otherwise modify informed consent 
requirements (ie, modification of consent). When a 
waiver or modification of consent has been granted 
by a research ethics committee, it should be reported 
and a justification given. It should be clear whose 
consent was waived and whether the waiver pertains 
to study participation, data collection, or both. Not 
all jurisdictions allow for a waiver or modification of 
consent. Information on data collection procedures in 
the trial, for example, whether data are anonymous or 
pseudo-anonymous, and whether they were routinely 
collected, can provide clarity around ethical aspects of 
the trial. When appropriate, it can be useful to include 
any participant consent forms in appendices, which 
will allow readers to infer precisely the information 
provided to participants.
Methods: Blinding
Item 11a: Blinding
Standard CONSORT item—If done, who was blinded 
after assignment to interventions (eg, participants, 
care providers, or those assessing outcomes) and how.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—If done, who was blinded 
after assignment to sequences (eg, cluster level 
participants, individual level participants, or those 
assessing outcomes) and how.
Example 1 (Blinding not possible)—“Blinding to the 
intervention (ie, the type of water being received) is 
not possible due to potential differences in turbidity of 
untreated and RBF (Riverbank Filtration)-treated river 
water.”43
Example 2 (Blinding partially possible)—“Residents 
did not know when the intervention was being 
implemented or what the programme elements 
were. Interviewers who administered the outcome 
questionnaires were masked to intervention 
implementation or depression treatment, and to 
previous test results. Data analysts were masked 
to whether a specific resident had been exposed to 
the intervention and to when the intervention was 
implemented in a unit, but were not masked during 
post-hoc analyses.”64
Explanation—SW-CRTs are often used to evaluate 
interventions for which it is impossible to blind 
participants or clusters to whether they are in the 
intervention or control condition, but nonetheless it is 
important to report clearly whether or not blinding was 
used and if so, who exactly was blinded to aspects of 
the trial (example 1).
Often outcomes are collected at multiple levels (eg, 
hospitals (eg, team climate outcomes), clinicians (eg, 
knowledge, skills, or practice outcomes), patients (eg, 
pain)). The possibility of blinding may be different 
depending on the level of participants (eg, clinicians 
or patients) and may depend on the type of consent 
required (item 10c). The degree of blinding should 
be reported at each level of the trial (eg, clusters, 
participants as in example 2) and whether the blinding 
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differed in control and intervention conditions. 
Researchers should also specifically report blinding 
with respect to all outcomes. Blinding of those 
assessing outcomes should be clearly reported.
A systematic review has found that most SW-CRTs 
do not report clearly who was blinded and what 
people were blinded to.19 Whether or not and who was 
blinded, and when, is best reported by the use of a 
timeline diagram.69
Item 11b: Blinding
Standard CONSORT item—If relevant, description of 
the similarity of interventions.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—If relevant, description of 
the similarity of treatments.
Explanation—In trials with a placebo it is important 
to provide evidence of the similarity of the control 
condition to the intervention condition (ie, to provide 
evidence of the blinding). However, in SW-CRTs it would 
be unusual to have a placebo and often participants 
are not blind to their allocation status. Sometimes, a 
minimal level of intervention is provided in the control 
condition in an attempt to keep participants blinded 
to their status as intervention or control participants. 
When appropriate, such minimal level interventions 
should be described in full.
Methods: Statistical methods
Item 12a: Statistical methods
Standard CONSORT item—Statistical methods used to 
compare groups for primary and secondary outcomes.
CONSORT cluster extension—How clustering was 
taken into account.
Extension for SW-CRTs—Statistical methods used 
to compare treatment conditions for primary and 
secondary outcomes including how time effects, 
clustering, and repeated measures were taken into 
account.
Example 1 (Allowance for clustering and secular 
trends)—“A generalised linear mixed model was used 
for categorical outcomes, and a linear mixed model 
was used for continuous outcomes, adjusting for age, 
gender, ethnicity and school terms (ie, secular trend). 
The cluster effect by school and correlation between 
repeated measurements on the same child over time 
were taken into account in the multilevel analysis.”63
Example 2 (Cluster level analysis)—“The primary 
outcome (diarrhoeal prevalence) will be calculated for 
each cell in the stepped wedge design by aggregating 
over all individuals surveyed in each village during 
each time period. Estimation of intervention effects 
will be obtained from a linear regression of the 
logarithm of the village-aggregated prevalence 
adjusting for seasonal effects and incorporating village 
as a fixed effect. The intervention effect coefficient will 
be exponentiated to produce an estimated relative 
reduction (with 95% confidence intervals) in the 
overall prevalence of diarrhoea in the intervention 
periods (post-RBF) compared with control periods 
(piped but unfiltered water). This analysis model 
controls for both clustering of individuals within 
villages and for repeated assessments of villages over 
time... We will use multiple-imputation to impute 
missing outcomes at the individual person level 
which will then be aggregated for the village-level 
analyses.”43
Example 3 (Intention-to-treat analysis)—“For the 
“intention-to-treat” analysis an indicator of whether an 
observation occurred pre- or post-randomisation was 
included in the regression model. To allow for delays in 
implementation a separate “per protocol” analysis was 
performed with the observations now placed into one 
of the three categories: “pre-randomisation,” “post-
randomisation but pre-implementation” and “post-
implementation…”34
Explanation—The statistical methodology should 
be clearly reported to allow replication. Where 
possible, it can be helpful to provide a reference to the 
statistical methodology used. In a SW-CRT, clusters are 
randomised to sequentially initiate the intervention. 
Observations collected under the control condition are 
therefore, on average, from an earlier calendar time 
than observations collected under the intervention 
condition. Changes external to the trial may create 
underlying secular trends. Likewise, participants, if 
repeatedly measured over the duration of the study, 
may get sicker or recover over time. This means that 
time is a potential confounder. Analysis of a SW-CRT 
should adjust for time effects irrespective of their 
statistical significance;54 failure to do so risks biasing 
the estimate of the intervention effect, which could 
lead to declaring an intervention effective when it 
is ineffective or ineffective when it is effective.10 It is 
therefore essential to report if and how time effects 
were allowed for. If time is measured continuously, time 
can be modelled parametrically; if time is measured 
discretely then time can be modelled categorically. 
Furthermore, SW-CRTs typically include only a 
small number of clusters and so prespecification of 
important prognostic factors to use in a fully adjusted 
analysis (in mitigation of the likelihood of imbalance 
due to sampling variation) might be undertaken;8  77 
and small sample corrections should be incorporated 
where appropriate. 
In a parallel CRT, randomisation at the level of 
the cluster needs to be allowed for at the analysis 
stage (unless cluster level data are being analysed). 
In a SW-CRT, as clusters (and possibly individuals) 
are repeatedly measured over time, there may 
be some reduction in the strength of correlation 
between measurements within the same cluster 
over time.12 Failure to appropriately model the 
correlation structure can lead to incorrect estimation 
of the precision of treatment effects.78 It is therefore 
important to clearly describe the correlation structure 
used in the analysis.
The analysis should also describe how deviations 
from the randomisation schedule were accommodated 
(example 3). A more detailed consideration of this 
point is given under item 16 (numbers analysed).
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Item 12b: Additional statistical methods
Standard CONSORT item—Methods for additional 
analyses, such as subgroup analyses and adjusted 
analyses.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Methods for additional 
analyses, such as subgroup analyses, sensitivity 
analyses, and adjusted analyses.
Example (Time varying effect of intervention)—
“Furthermore, a delayed intervention effect of the CCs 
(Case Conference i.e. intervention) is assumed because 
the nurses need time to implement the procedure. 
Thus, the duration of the intervention in months must 
be considered.”44
Explanation—SW-CRTs, like other trial designs, 
will commonly investigate subgroup differences and 
may perform adjusted analyses. In trials with a small 
number of clusters, investigating the sensitivity to 
model assumptions will be important.79
Of some importance in a SW-CRT is time 
by treatment interactions. Time by treatment 
interactions are treatment effects which change as 
the study progresses (not to be confused with the 
concept of “Imbalance of the design with respect to 
time,” see table 2). These changing treatment effects 
are important because observations contributing to 
the analysis will comprise a mixture of times since 
roll-out of the intervention. Interventions delivered 
at a single occasion (and not repeated to ensure it 
creates a permanent effect) might have an impact 
which changes with increasing time since roll-out 
(eg, the effect of the intervention might be quite large 
immediately after roll-out and then its impact might 
start to wane). If interventions are refined over time 
then their effect will also change over the duration of 
the study. Few trials, if any, have clearly investigated 
these time by treatment interactions,15  20 although 
many interventions have been assessed as being at 
risk of time by treatment interactions.15 The example 
above makes an acknowledgment of the possibility 
of a delayed effect, although gives limited detail as to 
how it will be investigated.
Of particular interest in a SW-CRT might be whether 
the intervention has a delayed effect (perhaps 
because its anticipated effect is not expected to 
materialise immediately (ie, a lag effect)); or if the 
intervention effect varies by time since exposure 
(eg, an effect that decays over time or an effect that 
improves over time), perhaps because the effect of 
the intervention might be expected to wane with 
increasing time since exposure, particularly so in 
educational type interventions;25 or perhaps due to 
the intervention being refined over the course of the 
roll-out.
Also of interest might be whether the effect of 
the treatment varies between sequences, perhaps 
because participants get sicker (or recover) with longer 
duration in the control condition and the treatment 
is not anticipated to have the same effect in sicker 
participants.14
Results: Participant flow
Item 13a: Participant flow
Standard CONSORT item—For each group, the numbers 
of participants who were randomly assigned, received 
intended treatment, and were analysed for the primary 
outcome.
CONSORT cluster extension—For each group, the 
numbers of clusters that were randomly assigned, 
received intended treatment, and were analysed for the 
primary outcome.
Extension for SW-CRTs—For each treatment condition 
or allocated sequence, the numbers of clusters and 
participants who were assessed for eligibility, were 
randomly assigned, received intended treatments, and 
were analysed for the primary outcome (fig 3).
Item 13b: Participant attrition
Standard CONSORT item—For each group, losses and 
exclusions after randomisation, together with reasons.
CONSORT cluster extension—For each group, losses 
and exclusions for both clusters and individual cluster 
members.
Extension for SW-CRTs—For each treatment condition 
or allocated sequence, losses and exclusions for both 
clusters and participants with reasons.
Example (Flowchart by treatment condition and 
sequence, cross-sectional design)—Supplementary 
materials, figure S2.32
Explanation—Information on the number of clusters 
and participants who were assessed for eligibility 
and outcomes along with the number of losses and 
exclusions (ie, withdrawals) allows the reader to assess 
the risk of differential inclusion and attrition.
Any flowchart should allow the reader to examine 
the nature of any differential inclusion and attrition by 
allocated sequence, treatment condition, and over time 
(see example). Because there are many different types 
of SW-CRTs there is unlikely to be one flowchart that 
will be applicable for all SW-CRTs. How the flowchart 
is constructed will depend on how many sequences 
and clusters there are, whether participants contribute 
repeated measures, and whether participants can 
join and leave the study. This information could be 
presented by allocated sequence but might also be 
presented by treatment conditions.
Including periods in the flowchart is important to 
allow for assessment of differential participation over 
time. When different participants are sampled in each 
period, each participant will, in theory, be exposed to 
either the intervention or control condition. In this case, 
summarising the number of participants by treatment 
condition is possible. Where the same participant 
contributes multiple measurements, each participant 
may provide measurements under both intervention 
and control conditions. In this case, summarising the 
number of participants by allocated sequence, along 
with the average number of measurements contributed 
by each participant, is more appropriate.
Reporting the number of clusters and participants 
approached, eligible, and included along with the 
reasons for non-participation is important to allow 
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an assessment of study generalisability, and perhaps 
even more importantly, of biases due to differential 
participation between treatment conditions (or 
sequences). For example, in a parallel CRT without 
blinding of participants to treatment condition at the 
time of recruitment, a higher rate of consent among 
those recruited to the intervention condition can 
indicate recruitment bias.69 Information on reasons 
as to why participants or clusters are not included 
allows a reader to assess the appropriateness of 
exclusions.
Results: Recruitment
Item 14a: Recruitment
Standard CONSORT item—Dates defining the periods of 
recruitment and follow-up.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Dates defining the steps, 
initiation of intervention, and deviations from planned 
dates. Dates defining recruitment and follow-up for 
participants.
Example 1 (Step dates)—“Twenty-two villages 
received the intervention in the second period (April-
June 2011), 36 in the third period (September-
November 2011), 35 in the fourth period (April-June 
2012), and 35 in the fifth period (September-November 
2012).”28
Example 2 (Deviations from planned dates)—“There 
were 60 study wards in the 16 randomised hospitals, of 
which 33 (22 ACE and 11 ITU) in 13 hospitals went on 
to implement the intervention, with a mean (SD) delay 
in implementation of 5 (4) months …and a mean (SD) 
duration of implementation of 12 (7) months. Eight 
wards began implementation very late, and for these 
the end of the trial was extended to December 31st 
2009 to ensure that they had a year of data collection 
post-implementation.”34
Explanation—Dates defining periods of recruitment 
of participants can be reported where appropriate; in 
some designs these dates will be at the beginning of the 
study before any crossover of clusters occurs; in other 
designs, recruitment will be continuous throughout 
the study. In some studies, there will be no direct 
Assessed for eligibility (n=no of clusters)
Randomised (n=no of clusters)
Sequence 3
Clusters allocated (n=)
Sequence 2
Clusters allocated (n=)
Sequence 1
Clusters allocated (n=)
Excluded (n=no of clusters):
  Not meeting inclusion criteria (n=)
  Declined to participate (n=)
  Other reasons (n=)
Assessed for eligibility (n=)
Received intervention (n=no of clusters,
  average cluster size, variance of cluster sizes)
Did not receive intervention, give reasons
  (n=no of clusters, average cluster size, variance of
  cluster sizes)
Assessed for eligibility (n=)
Received intervention (n=no of clusters,
  average cluster size, variance of cluster sizes)
Did not receive intervention, give reasons
  (n=no of clusters, average cluster size, variance of
  cluster sizes)
Assessed for eligibility (n=)
Received intervention (n=no of clusters,
  average cluster size, variance of cluster sizes)
Did not receive intervention, give reasons
  (n=no of clusters, average cluster size, variance of
  cluster sizes)
Period 1
Assessed for eligibility (n=)
Received intervention (n=no of clusters,
  average cluster size, variance of cluster sizes)
Did not receive intervention, give reasons
  (n=no of clusters, average cluster size, variance of
  cluster sizes)
Assessed for eligibility (n=)
Received intervention (n=no of clusters,
  average cluster size, variance of cluster sizes)
Did not receive intervention, give reasons
  (n=no of clusters, average cluster size, variance of
  cluster sizes)
Assessed for eligibility (n=)
Received intervention (n=no of clusters,
  average cluster size, variance of cluster sizes)
Did not receive intervention, give reasons
  (n=no of clusters, average cluster size, variance of
  cluster sizes)
Period 2
Assessed for eligibility (n=)
Received intervention (n=no of clusters,
  average cluster size, variance of cluster sizes)
Did not receive intervention, give reasons
  (n=no of clusters, average cluster size, variance of
  cluster sizes)
Assessed for eligibility (n=)
Received intervention (n=no of clusters,
  average cluster size, variance of cluster sizes)
Did not receive intervention, give reasons
  (n=no of clusters, average cluster size, variance of
  cluster sizes)
Assessed for eligibility (n=)
Received intervention (n=no of clusters,
  average cluster size, variance of cluster sizes)
Did not receive intervention, give reasons
  (n=no of clusters, average cluster size, variance of
  cluster sizes)
Period 3
Assessed for eligibility (n=)
Received intervention (n=no of clusters,
  average cluster size, variance of cluster sizes)
Did not receive intervention, give reasons
  (n=no of clusters, average cluster size, variance of
  cluster sizes)
Cluster under intervention condition                 Cluster under control condition
Assessed for eligibility (n=)
Received intervention (n=no of clusters,
  average cluster size, variance of cluster sizes)
Did not receive intervention, give reasons
  (n=no of clusters, average cluster size, variance of
  cluster sizes)
Assessed for eligibility (n=)
Received intervention (n=no of clusters,
  average cluster size, variance of cluster sizes)
Did not receive intervention, give reasons
  (n=no of clusters, average cluster size, variance of
  cluster sizes)
Period 4
Fig 3 | Specimen flowchart for a stepped wedge cluster randomised trial (SW-CRT) by allocated sequence and period
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participant recruitment, but identification of data from 
participants from routine data sources.
Reporting of other key dates is also important in a 
SW-CRT. These dates include the dates defining when 
the study was undertaken and dates defining the 
steps. Dates defining the start and end of the roll-out 
phase, as well as the dates of the steps are useful to 
demonstrate if the trial was implemented as planned 
(example 1). Dates should be presented so that they 
can be easily related to the planned timing of the steps 
as described in item 3a. Reporting deviations from 
planned dates is particularly important in the SW-CRT 
as they demonstrate deviations from the randomised 
schedule (example 2).
Dates defining implementation of interventions will 
allow assessment of when the intervention is fully 
implemented in each cluster. Dates defining actual 
implementation of the intervention should be specified. 
The realised time for an intervention to become fully 
implemented may differ from that which was planned. 
This allows assessment of whether all observations 
collected under the intervention condition were fully 
exposed to the intervention; it also allows assessment 
of whether any observations collected under the 
control condition were likely contaminated by the 
intervention. Reporting dates also allows inferences 
about external influences which may have affected 
secular trends.
Item 14b: Recruitment
Standard CONSORT item—Why the trial ended or was 
stopped.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Why the trial ended or was 
stopped.
Explanation—Readers are referred to the CONSORT 
statement and the extension to the CONSORT statement 
for examples and explanation.3 5
Results: Baseline data
Item 15: Baseline data
Standard CONSORT—A table showing baseline 
demographic and clinical characteristics for each 
group.
CONSORT cluster extension—Baseline characteristics 
for the individual and cluster levels as applicable for 
each group.
Extension for SW-CRTs—Baseline characteristics for 
the individual and cluster levels as applicable for each 
treatment condition or allocated sequence.
Example 1 (Baseline table by treatment condition, 
cross-sectional design)—Supplementary materials, 
table S2.
Example 2 (Baseline table by allocated sequence, 
open cohort design)—Supplementary materials, 
table S3.
Explanation—In a parallel CRT, a summary of the 
cluster and participant level characteristics at baseline 
by treatment condition can allow assessment of the 
success of randomisation and provides a description of 
the included sample. In trials with post-randomisation 
recruitment, this table can allow an assessment of 
potential biases.
The term “baseline” in a SW-CRT can be confusing 
because of the longitudinal nature of the design. 
We use the term “baseline characteristic” to mean 
a characteristic which was either measured before 
exposure to the control or intervention condition, or 
which is not expected to be influenced by the treatment 
conditions (eg, age). In designs in which observations 
are made on different participants in each period, 
these baseline characteristics will often pertain to 
measurements made just before the switch from control 
to intervention condition (ie, not at the start of the trial); 
whereas in designs where participants are repeatedly 
assessed, these characteristics might be measured 
before randomisation. Cluster level characteristics can 
often be measured before randomisation and are less 
likely to change over time.
For SW-CRTs in which observations are made on 
different participants in each period, the summary of 
baseline characteristics could be presented by treatment 
condition or by allocated sequence. For example, the 
DAVE Trial, which measures different participants in 
each period, reports its baseline table by treatment 
condition (see supplementary materials, fig S2).
For SW-CRTs in which the same participants 
are repeatedly assessed in each of the periods, the 
baseline characteristics of participants will normally 
be presented by allocated sequence rather than by 
treatment condition. This is because most participants 
will be observed first under the control and then 
intervention condition. The Depression Management 
Trial (see supplementary materials, fig S3) provides 
summary characteristics by allocated sequence.
Results: Numbers analysed
Item 16: Numbers analysed
Standard CONSORT—For each group, number of 
participants (denominator) included in each analysis 
and whether the analysis was by original assigned 
groups.
CONSORT cluster extension—For each group, number 
of clusters included in each analysis.
Extension for SW-CRTs—The number of observations 
and clusters included in each analysis for each 
treatment condition and whether the analysis was 
according to the allocated schedule.
Example 1 (Numbers by treatment condition)—“A 
total of 5295 surgical procedures were carried out 
throughout the stepped wedge cluster RCT, that is, 
2212 in control and 3083 (of which 2263 had the SSC 
performed) after implementation of the SSC (Surgical 
Safety Checklist). Patients (14.9%; 667/4475) 
underwent more than 1 procedure. The control and 
SSC study steps included 1778 and 2033 unique 
patients, respectively.”33
Example 2 (Intention-to-treat v per protocol)—“The 
flow diagram shows there were 60 study wards in the 
16 randomised hospitals, of which 33 (22 ACE and 
11 ITU) in 13 hospitals went on to implement the 
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intervention… For the primary outcome, intention-
to-treat analysis was conducted for the 60 wards 
randomised into the intervention, and per-protocol 
analysis was performed for the 33 implementing 
wards…”34
Explanation—The number of observations by 
treatment condition should be reported for analyses 
of all outcomes (example 1). For some outcomes this 
information will be included in a flowchart although 
not all flowcharts for a SW-CRT will give an immediate 
summary of this information by treatment condition. 
When the same participants are repeatedly measured 
across the time periods, each participant will have 
been exposed to both treatment conditions and so this 
information can be reported either by giving the total 
number of observations (by treatment condition) or as the 
number of participants in the study and average number 
of assessments per participant under each treatment 
condition. Where different participants contribute to 
each measurement period, it might be useful to have 
information on the number of participants per cluster 
period. Such information might be most easily reported 
in a diagram rather than in text (see fig 3).
Sometimes clusters (and perhaps participants) 
will not receive the intervention condition as per the 
randomisation schedule (example 2). In a parallel 
trial an intention-to-treat analysis performs the 
analysis according to the groups to which participants 
or clusters were originally assigned.22 In a SW-CRT 
this might be interpreted as analysis of clusters and 
participants treated as exposed to the intervention 
according to the dates of the randomisation schedule 
(ie, according to the planned dates). The application of 
this principle would mean that clusters are treated as 
exposed to the intervention if the observation comes 
from a period after the allocated crossover date. When 
a SW-CRT has randomised clusters to actual dates of 
transitioning from control to intervention, an intention-
to-treat analysis following this interpretation is logical.
Alternatively, a SW-CRT might be considered as 
randomising the order that the clusters transition 
from control to intervention (although when there are 
multiple clusters per sequence, several clusters share 
the same rank order). In this situation an intention-to-
treat analysis might be interpreted as analysis of clusters 
and participants treated as exposed to the intervention 
according to the order of the randomisation schedule (ie, 
according to the planned order of roll-out). The application 
of this principle would mean that clusters are treated as 
exposed to the intervention only after the intervention has 
been implemented in that cluster, provided the order of 
the allocation did not deviate from that planned.
Providing information on the number of clusters 
(and participants) contributing to all analyses 
allows assessment of whether the analysis has been 
conducted with respect to the randomised crossover 
schedule – which might not be in strict accordance 
with any prespecified dates; or to the actual crossover 
dates that may deviate from planned dates due to 
delays in implementation.
Sometimes a cluster may drop out from some 
purposively collected outcome assessments, but still 
contribute data from routinely collected sources for 
other outcome variables. If the numbers included 
in secondary analyses differ from those included in 
primary analyses, information on differential attrition 
(or participation) across clusters or periods can be 
provided in the text (similar to information depicted in 
the flowchart for the primary outcome, see fig 3).
Results: Outcomes and estimation
Item 17a: Outcomes and estimation
Standard CONSORT item—For each primary and 
secondary outcome, results for each group, and the 
estimated effect size and its precision (such as 95% 
confidence interval).
CONSORT cluster extension—Results at the individual 
or cluster level as applicable and a coefficient of 
intracluster correlation (ICC or k) for each primary 
outcome.
Extension for SW-CRTs—For each primary and 
secondary outcome, results for each treatment 
condition, and the estimated effect size and its precision 
(such as 95% confidence interval); any correlations (or 
covariances) and time effects estimated in the analysis.
Example 1 (Time adjusted treatment effect)—“A total 
of 321 (10.8%) unexposed patients were started on 
either antihypertensives or statins, and 577 (19.7%) 
exposed patients. The time-adjusted mean difference 
in proportion of patients initiating either treatment 
was 15.5% (95% confidence interval, 3.9 to 27.1).”52
Example 2 (Secular trend)—Supplementary 
materials, figure S3.
Example 3 (Correlations)—“The ICC in the time-
adjusted analysis for initiation of either treatment was 
0.014 (95% confidence interval, 0.005 to 0.038).”52
Explanation—A summary of the findings for each 
primary and secondary outcome should be provided 
for each treatment condition. This will allow a 
description of the severity or prevalence of the outcome 
in the sample (example 1). In addition, reporting of 
results by treatment condition allows estimation of an 
unadjusted effect of the intervention for comparison 
with a time adjusted effect (as in example 1).
Treatment effects should be reported along with 
confidence intervals. A SW-CRT which does not adjust 
for time is analogous to a simple uncontrolled before 
and after experiment; therefore, it should be clearly 
reported if the primary and secondary outcomes 
were adjusted for time (example 1). To allow an 
understanding of the potential impact of secular 
trends it can be helpful to describe the secular trend – 
either in a figure or as regression coefficients. Ideally 
this should be done by calendar time and should 
represent the trend in the clusters yet to be exposed 
to the intervention (example 2). In some SW-CRTs 
participants will be recruited at the very beginning 
of the trial and measured repeatedly. In chronic 
conditions these participants may naturally regress 
over the duration of the study; in acute conditions 
they may recover. While not a secular trend per se, 
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such effects still may lead to confounding of the 
intervention effect with time and so time should be 
adjusted for.
Reporting any estimated coefficients of ICCs 
can be informative for the planning of future 
trials (example 3). Correlation structures are more 
complex than in a parallel cluster trials conducted 
at a single cross-section in time; therefore, analysis 
(and reporting) of a single measure of correlation 
such as the ICC might not be sufficient.13 Relevant 
correlation coefficients might include correlations 
between observations in the same cluster and 
same time period (within period ICC); correlations 
between observations in the same cluster but 
different time periods (between period ICC), as well 
as between period and within period correlations on 
the same individual.12 It is important to be explicit 
about the types of correlations being reported.58 
Reporting of variance components is an alternative 
to ICCs, particularly for non-continuous outcomes.57 
When ICCs are reported for binary outcomes, clearly 
indicating the scale (eg, proportions or logistic 
scale) can help interpretation.80
Item 17b: Binary outcomes
Standard CONSORT item—For binary outcomes, 
presentation of both absolute and relative effect sizes 
is recommended.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—For binary outcomes, 
presentation of both absolute and relative effect sizes 
is recommended.
Explanation—In addition to reporting a relative 
measure of the effect of the intervention it can be 
helpful to report an absolute measure of the effect: 
while absolute measures of effects are more easily 
understood, relative measures of effects are often more 
stable across different populations.81
While reporting relative and absolute measures of 
effects is recommended, further methodological work 
is required to determine optimal methods of analysis 
that yield such estimates. Current approaches include 
fitting two separate models (eg, a binomial model 
with log link to report the relative risks and a binomial 
model with an identity link to report a risk difference) 
or by fitting one model and using a transformation to 
report the other measure of treatment effect.82
Model based methods for achieving estimates on 
both scales have been investigated in parallel CRTs in 
which the model is unadjusted for confounders;81 and 
others have evaluated the performance of these models 
when covariate adjustment is required.82
Results: Ancillary analyses
Item 18: Ancillary analyses
Standard CONSORT item—Results of any other analyses 
performed, including subgroup analyses and adjusted 
analyses, distinguishing prespecified from exploratory.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Results of any other analyses 
performed, including subgroup analyses and adjusted 
analyses, distinguishing prespecified from exploratory.
Explanation—There are several analyses that can 
be considered to examine deviation from model 
assumptions, for example, variations in secular 
trends across groups of clusters;10 interactions of the 
intervention effect with sequence; and whether the 
effect of the intervention might change with increasing 
duration of exposure (item 12b). In the reporting of 
these ancillary analyses, any limitations due to the 
assumptions made should be noted.
Results: Harms
Item 19: Harms
Standard CONSORT item—All important harms or 
unintended effects in each group (for specific guidance 
see CONSORT for harms).
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Important harms or 
unintended effects in each treatment condition (for 
specific guidance see CONSORT for harms).
Readers are referred to the CONSORT statement and 
the extension to the CONSORT statement for examples 
and explanation.3 5
Discussion
Item 20: Limitations
Standard CONSORT item—Trial limitations, addressing 
sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Trial limitations, addressing 
sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses.
Explanation—Estimated intervention effects from a 
SW-CRT will almost always be model-based estimates 
adjusting for time. There are a host of different models 
which can be used, but all make some assumptions. 
The assumptions made and potential limitations 
should be reflected on.
Item 21: Discussion
Standard CONSORT item—Generalisability (external 
validity, applicability) of the trial findings.
CONSORT cluster extension—Generalisability to 
clusters, individual participants, or both (as relevant).
Extension for SW-CRTs—Generalisability 
(external validity, applicability) of the trial findings. 
Generalisability to clusters, individual participants, or 
both (as relevant).
Readers are referred to the CONSORT statement and 
the extension to the CONSORT statement for examples 
and explanation.3 5
Item 22: Interpretation
Standard CONSORT item—Interpretation consistent 
with results, balancing benefits and harms, and 
considering other relevant evidence.
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CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Interpretation consistent 
with results, balancing benefits and harms, and 
considering other relevant evidence.
Readers are referred to the CONSORT statement and 
the extension to the CONSORT statement for examples 
and explanation.3 5
Other information
Item 23: Trial registration
Standard CONSORT item—Registration number and 
name of trial registry.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Registration number and 
name of trial registry.
Explanation—The International Committee of 
Medical Journal Editors (ICMJE) defines a clinical trial 
“as any research project that prospectively assigns 
people or a group of people to an intervention, with 
or without concurrent comparison or control groups, 
to study the cause-and-effect relationship between a 
health-related intervention and a health outcome.”83 
The ICMJE states that all medical journal editors should 
require clinical trials to be registered (before the first 
patient enrolment) as a condition of publication. SW-
CRTs of health related interventions meet the ICMJE’s 
definition of a clinical trial and so should, wherever 
possible, be registered as a clinical trial before the 
study start date.
Reporting the name of the trial registry and the unique 
trial registration number facilitates crosschecking with 
the associated registry entry and allows assessment 
of whether there are any important changes to the 
trial design, and the potential for any bias (such as 
outcome reporting bias). Further, reporting details 
of the trial registration facilitates linking of multiple 
publications from the same trial, which is of particular 
importance for systematic reviews. If the trial has not 
been registered, this should be stated along with the 
reason.
Studies examining trial registration rates have found 
that a large percentage of trials are not registered 
(eg, 28% to 44%).84  85  86 Further, in the trials that 
are registered, not all report the registration details 
in the trial publication, and not all are prospectively 
registered. A recent review that examined registration 
of SW-CRTs found that only 50% of SW-CRTs were 
prospectively registered.19
Item 24: Trial protocol
Standard CONSORT item—Where the full trial protocol 
can be accessed, if available.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Where the full trial protocol 
can be accessed, if available.
Readers are referred to the CONSORT statement and 
the extension to the CONSORT statement for examples 
and explanation.3 5
Item 25: Funding
Standard CONSORT item—Sources of funding and other 
support (such as supply of drugs), role of funders.
CONSORT cluster extension—No modification 
suggested.
Extension for SW-CRTs—Sources of funding and 
other support (such as supply of drugs), and the role 
of funders.
Readers are referred to the CONSORT statement and 
the extension to the CONSORT statement for examples 
and explanation.3 5
Item 26: Research ethics review
Standard CONSORT item—Not included.
CONSORT cluster extension—Not included.
Extension for SW-CRTs—Whether the study was 
approved by a research ethics committee, with 
identification of the review committee(s). Justification 
for any waiver or modification of informed consent 
requirements.
Example 1 (Full review)—“The study received 
ethical approval from the Sport and Health Sciences 
Ethics Committee at the University of Exeter (February 
2011).”42
Example 2 (Waiver of consent)—“This study was 
reviewed by the Regional Committee for Medical 
and Health Research Ethics (Ref: 2009/561), which 
advised that use of routinely collected anonymized 
patient data is clinical service improvement and thus 
no further approval or patient consent is required.”33
Explanation—The original CONSORT statement 
did not include an item on research ethics approval 
because it is an existing ICMJE requirement that 
research “involving human data” should indicate 
whether the research was reviewed by a research 
ethics committee.83 However, a systematic review 
found that only 75% of SW-CRTs reported review 
by a research ethics committee, possibly due to the 
classification of such studies, by some researchers, 
as service development or quality improvement. To 
encourage clear reporting about research ethics review 
of SW-CRTs we have therefore included this as a new 
item. This is consistent with the recent extension to 
the CONSORT statement for pilot studies, which also 
included this as a new item.27 An application number 
or reference number of the ethical approval should 
also be reported. If a study is deemed exempt from 
review by a research ethics committee, this should 
be reported together with a clear justification for the 
exemption from review.
Conclusions
The SW-CRT offers an exciting new opportunity to 
rigorously examine the effects of implementation, 
policy, and service delivery interventions. The 
design is appealing in many respects, but also 
provides many challenges. It has noteworthy risks 
for biases including bias due to temporal trends 
and within-cluster contamination, as well as 
method complexities such as changes in correlation 
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structures over time. Furthermore, perhaps because 
the design is being used in situations where 
researchers are not familiar with standards for 
reporting or conduct, SW-CRTs have been noted to 
be particularly prone to inadequacies of ethical 
reporting, including research ethics review and (in 
common with many cluster trials) identification 
of research participants. This extension of the 
CONSORT statement for SW-CRTs encourages 
researchers to reflect on the unique aspects of the 
SW-CRT and improve the clarity of reporting.
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